

**CHARACTERIZATION OF *STREPTOCOCCUS PNEUMONIAE*  
STRAIN ISOLATED FROM PNEUMONIA CASES OF CHILD  
PATIENTS**

**A THESIS**

**BY**

**MD. NAYEMUL BARI**

REGISTRATION NO: 1605456

SEMESTER: JULY- DECEMBER, 2018

SESSION: 2016

**MASTER OF SCIENCE (M.S)**

**IN**

**MICROBIOLOGY**



**DEPARTMENT OF MICROBIOLOGY  
HAJEE MOHAMMAD DANESH SCIENCE AND TECHNOLOGY  
UNIVERSITY, DINAJAPUR-5200  
DECEMBER, 2018**

**CHARACTERIZATION OF *STREPTOCOCCUS PNEUMONIAE*  
STRAIN ISOLATED FROM PNEUMONIA CASES OF CHILD  
PATIENTS**

**A THESIS**

**BY**

**MD. NAYEMUL BARI**

REGISTRATION NO: 1605456

SEMESTER: JULY- DECEMBER, 2018

SESSION: 2016

**Submitted to**

Department of Microbiology  
Hajee Mohammad Danesh Science and Technology University, Dinajpur  
In partial fulfillment of the requirements for the degree of

**MASTER OF SCIENCE (M.S.)**

**IN**

**MICROBIOLOGY**



**DEPARTMENT OF MICROBIOLOGY  
HAJEE MOHAMMAD DANESH SCIENCE AND TECHNOLOGY  
UNIVERSITY, DINAJAPUR-5200  
DECEMBER, 2018**

**CHARACTERIZATION OF *STREPTOCOCCUS PNEUMONIAE*  
STRAIN ISOLATED FROM PNEUMONIA CASES OF CHILD  
PATIENTS**

**A THESIS**

**BY**

**MD. NAYEMUL BARI**

REGISTRATION NO: 1605456

SEMESTER: JULY- DECEMBER, 2018

SESSION: 2016

*Approved as to style and content by*

.....  
**Professor Dr. Md. Mostafizer Rahman**

Supervisor

.....  
**Dr. Nazmi Ara Rumi**

Assistant Professor

Co-Supervisor

.....  
**Professor Dr. Md. Mostafizer Rahman**

Chairman

Department of Microbiology & Examination committee

**DEPARTMENT OF MICROBIOLOGY  
HAJEE MOHAMMAD DANESH SCIENCE AND TECHNOLOGY  
UNIVERSITY, DINAJAPUR-5200  
DECEMBER, 2018**

**Dedicated to**  
**My**  
**Beloved Parents**

## *ACKNOWLEDGEMENT*

*The author is ever grateful and indebted to the Almighty Allah without whose grace he would have ever been able to pursue his higher studies in this field of science and to complete his research work successfully for the degree of Master of Science (MS) in Microbiology.*

*The author sincerely desires to express his heart felt respect, deepest sense of gratitude, sincere appreciation and profound indebtedness to his respected teacher and Research Supervisor, Professor **Dr. Md. Mostafizer Rahman**, Chairman, Department of Microbiology, Faculty of Veterinary and Animal Science (FVAS), Hajee Mohammad Danesh Science and Technology University (HSTU), Dinajpur for his constant supervision, scholastic guidance, uncompromising principles, helpful advice, constant inspiration, affectionate feeling, radical investigation and constructive criticism in all phases of this study and preparing the manuscript.*

*The author finds it a great pleasure in expressing his heartfelt gratitude and immense indebtedness to his honorable teacher and respected Research Co-Supervisor, **Dr. Nazmi Ara Rumi**, Assistant Professor, Department of Microbiology, Faculty of Veterinary and Animal Science (FVAS), Hajee Mohammad Danesh Science and Technology University (HSTU), Dinajpur, for her sympathetic supervision, kind co-operation, inspiration and valuable suggestions, constructive criticism and valuable advice for the completion of the research work and preparation of the thesis.*

*The author wishes to express his cordial respect and profound gratitude to his honorable teachers Professor **Dr. Md. Khaled Hossain**, **Dr. Mir Rowshan Akter**, Associate Professor, **Dr. Farzana Afroz**, Assistant Professor, **Dr. Mst. Deloara Begum**, Assistant Professor, Department of Microbiology, FVAS, HSTU, Dinajpur.*

*The author expresses his cordial appreciation to all the office staff of the Department of Microbiology FVAS, HSTU, Dinajpur. The author expresses heartfelt gratitude and gratefulness to his beloved parents, friends **Mahmudul Hasan**, **Nabil Mahmud** & **Md. Aolad Hossain** & all well wishers for their blessing, inspiration, sacrifice and moral support which opened the gate and paved the way to his higher studies and also provided his with the best of everything in his life. Finally the author is extending his cordial thanks to all of his friends, relatives and well wishers.*

*The Author*

*December, 2018*

## ABSTRACT

*Streptococcus pneumoniae* is a leading cause of global morbidity and mortality in children causing pneumonia. The increasing incidence of antibiotic-resistant *S. pneumoniae* strains worldwide poses a threat to the effective treatment of these infections. For this purpose, the present research was conducted during the period of January–November 2018. The samples were collected from three main hospitals of Dinajpur district of Bangladesh. A total of 40 samples were randomly collected & analyzed through different bacteriological, biochemical, molecular & antibiotic susceptibility testing. Out of 40 samples, positive cases of pneumonia were found to be 37.5% & 15 isolates were isolated. The Frequency of pneumonia in relation to age were 3-5yrs (50%), 6-8yrs (33.33%), 9- 11yrs (25%) & 12-15 (20%). Distribution of organism based on age difference were 3-5 years (7%), 6-8 years (20%), 9-11 years (6.67%) & 12-15 years (30%). The present study reveals that the study area had no significant effect ( $P > 0.05$ ), but age ( $P < 0.05$ ) & socio-economic status ( $P < 0.05$ ) had significant effects on the prevalence of pneumonia in pneumonia patients. In study area, the highest prevalence was found in M Abdur Rahim Medical College Hospital (40%), followed by Arobindo Shishu Hospital (33.33%) & Islami Bank Community Hospital (40%) respectively. Among the age group, the prevalence of pneumonia was highest (50%) in 3-5 years age group, then 33.33% in 12-15 years age group, 25% in 6-8 years age group & 20% in 9-11 years age group. Highest prevalence of pneumonia was found in poor socio-economic status (54.54%), followed by medium (16.66%) & rich (16.66%) socio-economic condition respectively. *Streptococcus pneumoniae* was characterized by 16S rRNA Sequencing & the identified strain was *Streptococcus pneumoniae* NBRC102642. The antibiotic study revealed that all of the isolates of *Streptococcus pneumoniae* were resistant to most of the drugs, but found sensitive to Neomycin, Kanamycin & Streptomycin followed by Erythromycin, Azithromycin & Bacitracin. Avoidance of indiscriminate use of antibiotics & development of nationwide awareness can play an important role for the prevention of pneumonia.

## CONTENTS

| CHAPTER            | TITLE   | PAGE<br>NO.   |
|--------------------|---|---------------|
|                    | <b>ACKNOWLEDGEMENTS</b>   | <b>i</b>      |
|                    | <b>ABSTRACT</b>   | <b>ii</b>     |
|                    | <b>CONTENTS</b>   | <b>iii-vi</b> |
|                    | <b>LIST OF TABLES</b>   | <b>vii</b>    |
|                    | <b>LIST OF PLATE</b>  | <b>viii</b>   |
|                    | <b>ABBREVIATIONS</b>  | <b>ix-x</b>   |
| <b>CHAPTER I</b>   | <b>INTRODUCTION</b>   | <b>1-3</b>    |
| <b>CHAPTER II</b>  | <b>REVIEW OF LITERATURE</b>   | <b>4-22</b>   |
|                    | 2.1 Isolation, Molecular characterization & anti-<br>microbial resistance of <i>Streptococcus pneumoniae</i><br>in child patients | 04-22         |
| <b>CHAPTER III</b> | <b>MATERIALS AND METHODS</b>  | <b>23-39</b>  |
|                    | 3.1 Study design  | 23            |
|                    | 3.2 Study area and period   | 23            |
|                    | 3.3 Collection of Sample  | 24            |
|                    | 3.4 Experimental Layout   | 24-25         |
|                    | 3.5 Sample processing, isolation and identification of<br>bacteria  | 26            |
|                    | 3.6 Bacteriological Media   | 26            |
|                    | 3.6.1 Media used in the Experiment  | 26            |
|                    | 3.6.1.1 Solid Media   | 26            |
|                    | 3.6.1.2 Liquid Media  | 27            |
|                    | 3.6.2 Reagent   | 27            |
|                    | 3.7 Materials used for bacterial genomic DNA isolation  | 28            |
|                    | 3.7.1 Meterials used for Polymerase Chain<br>Reaction   | 28            |
|                    | 3.8 Glassware and Appliances  | 29            |
|                    | 3.9 Morphological Characterization of Bacteria by<br>Gram's Staining Method   | 29            |
|                    | 3.10 Preparation of Gram's staining solution  | 29            |

---

|        |   |    |
|--------|---|----|
| 3.10.1 | Gram staining procedure   | 30 |
| 3.11   | Biochemical Tests   | 30 |
| 3.11.1 | Catalase Test   | 31 |
| 3.11.2 | Indole Test   | 31 |
| 3.11.3 | Methyl Red Test (MR)  | 31 |
| 3.11.4 | Voges-Proskauer Test (VP)   | 31 |
| 3.11.5 | Triple Sugar Iron (TSI) Test  | 31 |
| 3.11.6 | Bile Solubility Test  | 32 |
|        | 3.11.6.1 Reagents for Bile Solubility<br>Test                       | 32 |
| 3.12   | Antibiotic susceptibility testing                                   | 32 |
| 3.12.1 | Antimicrobial agents with their disc<br>concentration               | 33 |
| 3.13   | Maintenance of stock culture by sterile buffered<br>glycerin method | 33 |
| 3.14   | Laboratory Preparation  | 34 |
| 3.15   | Preparation of Culture Media  | 34 |
| 3.15.1 | Solid Media   | 34 |
|        | 3.15.1.1 Plate count agar (PCA)                                     | 34 |
|        | 3.15.1.2 Nutrient agar Media  | 34 |
|        | 3.15.1.3 TSI Slant  | 34 |
|        | 3.15.1.4 Blood Agar   | 35 |
| 3.15.2 | Liquid Media  | 35 |
|        | 3.15.2.1 Nutrient Broth   | 35 |
|        | 3.15.2.2 Methyl red- Voges Proskauer<br>(MR-VP) Broth               | 35 |
| 3.16   | Preparation of Reagents   | 36 |
| 3.16.1 | Methyl red solution   | 36 |
| 3.16.2 | Alpha- Naphthol solution  | 36 |
| 3.16.3 | Kovac's Reagent   | 36 |
| 3.16.4 | Potassium hydroxide solution  | 36 |
| 3.16.5 | Phosphate buffered Saline Solution                                  | 36 |

---



---

|                   |   |              |
|-------------------|---|--------------|
| 3.17              | PCR Amplification, Sequencing of 16S rRNA<br>Genes with Universal Primers and Phylogenetic<br>Analysis of <i>Streptococcus pneumoniae</i> | 37           |
| 3.17.1            | Basic protocol of bacterial genomic DNA<br>isolation  | 37           |
| 3.17.2            | PCR amplification & sequencing of 16S<br>rRNA   | 38           |
| 3.17.3            | Electrophoresis   | 38           |
| 3.17.4            | Nucleotide sequence accession number<br>and BLAST analysis  | 39           |
| <b>CHAPTER IV</b> | <b>RESULTS</b>  | <b>40-58</b> |
| 4.1               | Results of microbial assessment of collected blood<br>and nasopharyngeal swab samples by total viable<br>counts                           | 40           |
| 4.2               | Isolation and identification of bacteria by different<br>bacteriological Methods  | 41           |
| 4.2.1             | Results of Cultural Examination   | 41           |
| 4.2.2             | Results of nasopharyngeal swab sample<br>inoculation on Nutrient broth, Nutrient<br>agar & Blood agar:                                    | 42           |
| 4.2.3             | Results of Blood sample inoculation on<br>Nutrient broth, Nutrient agar & Blood agar:   | 43           |
| 4.2.3.1           | Nutrient broth  | 43           |
| 4.2.3.2           | Nutrient Agar   | 43           |
| 4.2.3.3           | Blood Agar  | 44           |
| 4.2.4             | Results of Microscopic Examination  | 44           |
| 4.3               | Results of Biochemical Tests  | 45           |
| 4.3.1             | Catalase Test   | 45           |
| 4.3.2             | Oxidase Test  | 46           |
| 4.3.3             | Methyl-Red Test   | 46           |
| 4.3.4             | Voges-Proskaur Test   | 47           |
| 4.3.5             | Indole Test   | 47           |
| 4.3.6             | Lactose Fermentation Test   | 48           |

---

---

|                   |   |              |
|-------------------|---|--------------|
| 4.3.7             | TSI (Triple Sugar Iron) Test  | 48           |
| 4.3.8             | Bile Solubility Test  | 49           |
| 4.4               | Frequency of pneumonia among pneumonia patients based on different categories   | 49-50        |
| 4.5               | Prevalence of pneumonia among pneumonia patients  | 51           |
| 4.6               | Result of PCR Amplification, Sequencing of 16S rRNA Genes with Universal Primers and Phylogenetic Analysis of <i>Streptococcus pneumoniae</i> | 52           |
| 4.6.1             | Contig Sequence of <i>Streptococcus pneumoniae</i>  | 53           |
| 4.6.2             | Phylogenetic tree analysis of <i>Streptococcus pneumoniae</i>   | 54           |
| 4.6.3             | Result of Electropherogram  | 54           |
| 4.7               | Results of Antibiotic Sensitivity Tests   | 55           |
| 4.7.1             | Antibiotic Sensitivity pattern of <i>Streptococcus pneumoniae</i>   | 56-58        |
| <b>CHAPTER V</b>  | <b>DISCUSSION</b>   | <b>59-60</b> |
| <b>CHAPTER VI</b> | <b>CONCLUSION</b>   | <b>61</b>    |
|                   | <b>REFERENCES</b>   | <b>62-70</b> |

---

## LIST OF TABLES

| TABLE NO. | TITLE  | PAGE NO. |
|-----------|--|----------|
| 01        | PCR Reaction Mixture for 16s rRNA  | 28       |
| 02        | Condition of PCR   | 38       |
| 03        | Results of total viable counts in PCA agar   | 40       |
| 04        | The results of cultural characteristics of the bacteria which were isolated from blood & nasopharyngeal swab samples of pneumonia patients | 41       |
| 05        | Results of Biochemical Tests   | 45       |
| 06        | Frequency of pneumonia among pneumonia patients  | 49       |
| 07        | Frequency of pneumonia in pneumonia patients in relation to age  | 50       |
| 08        | Distribution of pneumonia patients according to sample collection and types of bacteria  | 50       |
| 09        | Distribution of organism based on age difference   | 50       |
| 10        | Prevalence of pneumonia based on study area, age & socio-economic status   | 51       |
| 11        | Result of antibiotic sensitivity test for <i>Streptococcus pneumoniae</i>  | 55       |

## LIST OF PLATES

| PLATE<br>NO. | TITLE  | PAGE<br>NO. |
|--------------|--|-------------|
| 01           | Sample Collection  | 23          |
| 02           | The schematic illustration of the experimental layout  | 25          |
| 03           | Colony count on Plate Count Agar plate   | 41          |
| 04           | Fresh Nutrient broth (Right), Turbidity on Nutrient broth (Left).  | 42          |
| 05           | Fresh Nutrient agar plate (Right), Organisms on Nutrient agar showing convex, circular, white colony (Left).                             | 42          |
| 06           | Fresh blood agar plate (Right), Alpha hemolytic colonies on blood agar (Left).   | 42          |
| 07           | Uniform turbidity  | 43          |
| 08           | Culture on Nutrient Agar plate with smooth & gray white colonies   | 43          |
| 09           | Alpha hemolytic colonies on blood agar   | 44          |
| 10           | Gram positive spherical chain shape cocci were found on Gram's staining  | 44          |
| 11           | No bubble production indicates negative result in Catalase test.   | 45          |
| 12           | No purple colour development indicates a negative test & absence of oxydase enzyme.  | 46          |
| 13           | Methyl-Red test result was positive indicated by colour change of the medium to bright red ring formation (right) & the left is control. | 46          |
| 14           | The result of Voges-Proskauer test was negative indicated by no red color change of the medium (right) & control (left).                 | 47          |
| 15           | No cherry red color ring formation indicates negative indole test (right) & control (left).  | 47          |
| 16           | Colour change of the medium from red to orange or yellow indicates positive result (right) & control (left).                             | 48          |
| 17           | Triple Sugar Iron test showing control (left) & positive (right).  | 48          |
| 18           | Clearing of turbidity in test suspension indicates positive result (right) & the left is control.  | 49          |

## ABBREVIATIONS

---

|        |   |  |
|--------|---|--|
| DCC    | = | Day Care Centre  |
| ED     | = | Emergency Department                                       |
| EUCAST | = | European Committee on Antimicrobial Susceptibility Testing |
| MDR    | = | Multidrug Resistance                                       |
| MIC    | = | Minimal Inhibitory Concentration                           |
| PCC    | = | Primary Care Centres                                       |
| PCV    | = | Pneumococcal Conjugate Vaccine                             |
| PISP   | = | Penicillin Intermediate <i>Streptococcus pneumoniae</i>    |
| PNSP   | = | Penicillin Non-susceptible <i>Streptococcus pneumoniae</i> |
| PRSP   | = | Penicillin Resistant <i>Streptococcus pneumoniae</i>       |
| PSSP   | = | Penicillin Susceptible <i>Streptococcus pneumoniae</i>     |
| RTI    | = | Upper Respiratory Tract Infection                          |
| SPn    | = | <i>Streptococcus pneumoniae</i>                            |
| SPSS   | = | Statistical Package for the Social Sciences                |
| WHO    | = | World Health Organization                                  |
| CF     | = | Cystic Fibrosis  |
| PCR    | = | Polymerase Chain Reaction                                  |
| FEV1   | = | Forced Expiratory Volume in one second                     |
| FVC    | = | Forced Vital Capacity                                      |
| CBA    | = | Columbia Blood Agar  |

|      |   |   |
|------|---|---|
| CHOC | = | Chocolate Agar                              |
| DNA  | = | Deoxyribonucleic Acid                       |
| CFU  | = | Colony Forming Unit                         |
| TNTC | = | Too Numerous to Count                       |
| IQR  | = | Interquartile Range                         |
| RR   | = | Relative Risk                               |
| CLSI | = | Clinical and Laboratory Standards Institute |
| mm   | = | Millimeter                                  |
| NT   | = | Non-typable                                 |
| N/A  | = | Not applicable                              |

# CHAPTER I

## INTRODUCTION

*Streptococcus pneumoniae* remains a leading cause of serious infections and deaths in young children and the elderly globally (O'Brien *et al.*, 2009). As global efforts to prevent and control pneumococcal disease gain momentum, a good understanding of the population structure of *Streptococcus pneumoniae*, including the circulating pneumococcal serotypes and genotypes would be critical in guiding the development of appropriate interventions. Some studies have reported changes in circulating serotypes causing invasive disease and nasopharyngeal carriage in different parts of the world (Ubukata *et al.*, 2015; Devine *et al.*, 2017). However, most of these studies have been conducted in developed country settings with few in developing countries and there remain large gaps in our understanding of the pneumococcal population structure in developing countries where the burden of disease is disproportionately highest. In addition, changes in recent times, such as the increasingly widespread introduction of routine pneumococcal vaccination and changing patterns of HIV prevalence, could have an impact on the circulating pneumococcal serotypes and genotypes. The estimated incidence of community-acquired pneumonia among children under five years of age in developing countries is approximately 151.8 million new cases per year, 11-20 million of which require hospitalization (Rudan *et al.*, 2004). In developing countries, pneumonia occurs more often and is more severe than in developed nations, and carries higher incidence and mortality rates; pneumonia accounts for one fifth of under-five deaths in the developing world (Bryce *et al.*, 2005).

Regarding penicillin susceptibility of *S. pneumoniae*, minimum inhibitory concentration (MIC) breakpoints for penicillin were first established in the late 1970s, in response to the need for ensuring successful treatment of pneumococcal meningitis. Over the past three decades, increasing MICs to penicillin have emerged in pneumococci, and the percentage of penicillin-intermediate and penicillin resistant strains has risen (Berezin *et al.*, 1996; Whitney *et al.*, 2000). In a study conducted by the Regional Vaccine System Project (Projeto de Sistema Regional de Vacinas, SIREVA) between 2000 and 2005, of a total of 8,993 pneumococcal isolates (36.4% of which obtained from patients with pneumonia), 37.8% were penicillin-resistant (Castaned *et al.*, 2009). In light of this growing resistance, penicillins are increasingly being rejected for both empirical and susceptibility-guided

treatment, in favor of more expensive, broad-spectrum antibiotics. However, retrospective and prospective studies in adult and pediatric populations showed that the outcomes of pneumococcal pneumonias caused by purportedly resistant strains but treated with penicillin antibiotics did not differ from those obtained with other antimicrobial agents, suggesting that meningitis breakpoints did not apply to pneumonia. (Palleres *et al.*, 1987; Friedland/Klugman, 1992). Later multicenter studies confirmed these results (Song *et al.*, 2004; Yu *et al.*, 2003). *Streptococcus pneumoniae* is the most common cause of community-acquired respiratory tract infections such as otitis media, sinusitis, and pneumonias (Ishida *et al.* 2008). Globally, pneumococcal diseases account for 1 to 2 million deaths annually in both extremes of age. (Mulholland, 1999). It is supposed to be a very sensitive organism to routine antibiotics especially to penicillins. However, with the isolation of the first clinically significant penicillin-resistant pneumococcus (PRP) in 1967, many studies from different parts of the world have reported an increasing emergence of PRP (Collignon & Bell, 1996). At present, there are not only reports of resistant strains of *S. pneumoniae* to the beta lactam group of antibiotics, but there is also an emergence of multidrug-resistant strains (Lalitha & Manoharan, 2002).

*Streptococcus pneumoniae* remains a major cause of morbidity and mortality worldwide. Pneumococcus is a commensal of the upper respiratory tract of humans. However, it is also a human pathogen responsible for several respiratory tract infections & serious invasive pneumococcal diseases, such as sepsis and meningitis (O'Brien *et al.*, 2009). Pneumococcal disease has higher incidence among young children, the elderly and the immunocompromised of all ages. Within this latter group, the risk for pneumococcal infection will vary according to the underlying medical conditions but is several folds higher than among healthy people. For example, a study from Canada found that the incidence of IPD among hematopoietic stem cell transplant patients was 30-fold higher than in the general population (Kumar *et al.*, 2008).

As the epidemiology of pneumococcal disease varies with time and place, periodic reassessment with monitoring of prevalent serotypes and patterns of resistance is required for better therapeutic guidance and definition of control strategies. With that in mind, the main objectives of this study were to identify the *S. pneumoniae* serotypes most frequently isolated from children hospitalized for invasive pneumonia; compare these serotypes with those included in conjugate vaccines; and analyze their susceptibility to the antimicrobial agents most often used in pediatric practice. By considering the above-



mentioned justification the current study, were, therefore set with the following objectives.

### **Research Objectives**

- To examine the prevalence and risk factors of carriage of *S. pneumoniae* in the prevaccination era in young children.
- Isolation & identification of *streptococcus* spp. in child patients causing pneumonia.
- Molecular characterization of *streptococcus* spp. by PCR, DNA sequencing & Phylogenetic tree analysis.
- To determine the antibiotic sensitivity pattern of the isolated bacteria.

## CHAPTER II

### REVIEW OF LITERATURE

Every year in developing countries, some 4.5 million persons, most of them under 5 years of age, die of acute respiratory infections (Berman S, 1991). Most ARI episodes are caused by viral agents and are self-limiting, but the bacterial pneumonias, which occur less frequently, carry a much higher risk of complications and death (Shann, 1986). *Streptococcus pneumoniae* (pneumococcus) and *Haemophilus influenzae* are the two bacterial pathogens most commonly isolated in pediatric pneumonia (Paisley *et al.*, 1984). Since these microorganisms can colonize the upper respiratory tract, aspiration of secretions may lead to pneumonia, especially if an individual's susceptibility to a bacterial infection were increased by malnutrition, viral infection, or other factors that would change the immune response (Musher *et al.*, 1992). Colonization of the upper airways by *S. pneumoniae* can occur during the first few days of life; early colonization is associated with living in a large family and a higher risk of suffering from the disease (Gray *et al.*, 1980).

#### **2.1. Isolation, Molecular characterization & Anti-microbial resistance of *Streptococcus pneumoniae* in child patients**

**Ebruke *et al.*, 2018.** In West Africa, *Streptococcus pneumoniae* remains a leading cause of deaths in young children and serotype 1 strains are particularly important in causing invasive pneumococcal disease despite being rare in nasopharyngeal carriage. The *S. pneumoniae* ST217 clonal complex, consisting of ST217 and the various locus variants has been shown to be the predominant pneumococcal serotype 1 clone in the sub-region. It is unclear how the recent introduction of pneumococcal conjugate vaccine in countries in the sub-region could affect patterns of pneumococcal disease. Improving our understanding of the unique nature of pneumococcal serotype 1 strains within the context of other pneumococcal serotypes circulating in West Africa prior to introduction of PCV would be critical in interpreting any subsequent changes in patterns of disease in this region. Epidemiological studies on *S. pneumoniae* strains in The Gambia revealed that a new dominant clone of serotype 1, ST3081, a single locus variant of ST217, emerged and appeared to have spread across the whole country. ST3081 appeared to have replaced ST618, a triple locus variant of ST217 and the previously dominant pneumococcal serotype 1 lineage circulating in The Gambia for over a decade earlier. This thesis, which

also evaluated antimicrobial resistance patterns, showed that ST3081 isolates were more resistant to co-trimoxazole than ST618 isolates.

**Htoon *et al.*, 2018.** A cross-sectional, laboratory-based descriptive study was carried out on 231 ARI patients who were aged 1 month to less than 5 years attending YCH from 2013 to 2015. Nasopharyngeal swab specimens were taken after obtaining informed consent from the parents or guardians of the patients. Antimicrobial susceptibility profile was determined by modified Kirby-Bauer method. In addition, molecular serotyping of *S. pneumoniae* was done by Sequential Multiplex Polymerase Chain Reaction. The isolation rate of *S. pneumoniae* was 7.4% (17/231). A total of nine different serotypes were detected. The most common serotype was found to be 6A/6B/6C/6D (52.9%) followed by non-type able serotypes (29.4%), 19F, 23F and 35F/47F serotypes (11.8% each) and 23A, 11A/11D, 34 and 20 serotypes (5.9% each). Carriage of multiple serotypes was observed in 29.4% of *S. pneumoniae* isolates. 70.6% of *S. pneumoniae* isolates were found to be penicillin non-susceptible and multi-drug resistance was observed in 41.2% of strains.

**Michel *et al.*, 2018.** A cross sectional study was carried out from May to October 2014. HIV infected patients suspected of LRTIs attending the Center Medical laboratory and those followed up at the authorized treatment center of Yaounde Military Hospital in Cameroon were enrolled. Sputum was collected from each patient and cultured; identification of microorganisms was performed following standard methods. The disk diffusion method was used for antibacterial susceptibility testing according to the Antibiogram Committee of French Society for Microbiology guidelines. a total of 51 (25.5%) isolates of *S. pneumoniae* were recovered from sputum samples obtained from 200 HIV infected patients aged 19-66 years old (mean age: 36±10.087 years old); 144 (72%) of them were female (sex ratio M/F: 1/3). *S. pneumoniae* carriage was not age dependent (P = 0.384) and was significantly higher in male compared to female (P = 0.008). *S. pneumoniae* isolates were susceptible to amoxicillin-clavulanic acid (100%), pristinamycin (100%), erythromycin (100%) and cefixime (98.04 %). Highest resistance rates were recorded with fusidic acid (100%), fosfomycin (100%) and tetracycline (100%).

**Marta et al., 2017.** Evaluate the susceptibility profile of serotypes of *Streptococcus pneumoniae* associating them with pneumococcal invasive diseases, as well as antimicrobial therapies. This is a retrospective cross-sectional research involving secondary data from 1998 to 2013, in the northeastern macroregion of Sao Paulo state, Brazil, composed of Araraquara, Barretos, Franca and Ribeirao Preto regions, with 90 municipalities. At Instituto Adolfo Lutz, isolated strains from patients with PID were subjected to identification, serotyping and antimicrobial susceptibility testing. Results: From 796 strains analyzed, 14.8% ( $n = 118$ ) were resistant to penicillin, being 3% ( $n = 24$ ) with intermediate resistance and 11.8% ( $n = 94$ ) with full resistance, especially in patients with meningitis. Moreover, resistance to ceftriaxone was 5.3%: 34 (4.3%) with intermediate resistance and 8 (1%) with full resistance. We point out that the greatest level of resistance profiles was observed against sulfamethoxazole/trimethoprim: 350 (49.4%). On the other hand, antimicrobial susceptibility was described above 90% to chloramphenicol: 99.6% ( $n = 696$ ), erythromycin: 94.7% ( $n = 664$ ), ceftriaxone: 94.7% ( $n = 754$ ) and fully susceptible to vancomycin. Among the 18 most common serotypes, 9V and 14 showed less susceptibility to SMT, to penicillin and ceftriaxone; 19A to SMT and penicillin; 1 to SMT; 12F and 3 to chloramphenicol; 6A to SMT; 6B 23F to erythromycin and penicillin.

**Sedigheh et al., 2017.** In total, 73 isolates were collected and diagnosed as *S. pneumoniae*. Isolates were susceptible to ofloxacin 95.9%, vancomycin 93%, penicillin 78%, trimethoprim-sulfamethoxazole 61.6%, ceftriaxone 53.5%, meropenem 52%, cefotaxime 46.5%, and erythromycin 8.2%. Of the 15 PRSP isolates, the *pbp2b* gene was identified in 12 (80%). In 1 penicillin-intermediate *S. pneumoniae* isolate the *pbp2b* was detected.

**Fouzia et al., 2017.** This was a cross-sectional study conducted in the Department of Microbiology, Dow Diagnostic Reference and Research Laboratory, Karachi, Pakistan, during the period of January 2014 to October 2015. Isolation and identification of clinical isolates were performed by using standard and specific methods. Antibiotic susceptibility was performed by using Kirby Bauer method. Maximum numbers of *S. pneumoniae* were recovered from sputum, pus and blood and a higher percentage of the organisms were isolated from females. Among non-invasive *S. pneumococcal* infections, children, adolescents and adults were found to be highly resistant against Cotrimoxazole, Clindamycin and Ofloxacin, respectively. In invasive *S. pneumococcal* infections, highest

resistance was observed against Penicillin G, Cotrimoxazole and Macrolides in children, adolescents and adults, respectively.

**Araceli et al., 2016.** A total of 126 pneumococcal isolates were collected. Pneumonia was the most frequent diagnosis (40.5%), followed by meningitis (29.4%), septicemia (16.7%), and other clinical entities, including otitis media and conjunctivitis (13.5%). The most frequent serotypes before the introduction of heptavalent pneumococcal conjugate vaccine (PCV7) were 19F, 23F, 7F, and 35B. Serotypes 3, 6A, 10A, 12F, and 15A/B increased after the introduction of PCV7. Serotype 19A was isolated most frequently in the pneumonia and meningitis cases only after the introduction of PCV7, and it displayed a high resistance to penicillin.

**Takafumi et al., 2016.** All strains of *S. pneumoniae* were isolated from clinical specimens collected from pediatric patients. The minimum inhibitory concentration was measured and the strains were classified according to the Clinical Laboratory Standards Institute criteria. The isolation rates of penicillin-intermediate resistant *S. pneumoniae* (PISP) and penicillin-resistant *S. pneumoniae* (PRSP) were compared based on seven patient factors. Logistic regression analysis was also performed. The sum of the isolation rates for PISP and PRSP for each period was 64.6%, 67.0%, 56.2%, 76.9% and 49.5%, respectively. Among the patient factors, age category 1 (<3 years, ≥3 years), age category 2 (infant, toddler and preschooler, schoolchild), siblings (absence, presence), and pre-treatment with antimicrobial agents (absence, presence) were associated with significant differences in the isolation rate of PISP + PRSP. An interaction was observed between pre-treatment with antimicrobial agents and schoolchild, and the isolation rate of PISP + PRSP was higher in patients with both pretreatment with antimicrobial agents and schoolchild.

**Indre et al., 2016.** A total of 900 children under six years of age who presented to primary care centre or a hospital emergency department with acute respiratory tract infection were enrolled in the study. Nasopharyngeal swabs were obtained and cultured for SPn. Positive samples (n=367) were serotyped and tested for antimicrobial susceptibility. Associations of pneumococcal non-susceptibility with study site, season, age, sex, attendance of day care centre and treatment with antimicrobials (between one and six months prior the study) were evaluated. About a half (56.7 %) of SPn strains were susceptible to all the antibiotics tested. Pneumococcal non-susceptibility to penicillin,

erythromycin, clindamycin and trimethoprim–sulphamethoxazole was 15.8, 21.3, 16.9 and 27.3 %, respectively. None of the tested isolates was resistant to norfloxacin or vancomycin. We found a geographical variation of pneumococcal resistance within the cities of the country. Age, sex, the attendance of day care centre and treatment with antimicrobials prior the study was not significantly associated with a carriage of non-susceptible SPn strains. Among non-susceptible SPn serotypes, 67.9 %–82.4 % were present in currently available pneumococcal conjugate vaccines.

**Jailton *et al.*, 2016.** In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Brazilian childhood vaccination programme. Concerns have been raised that non-vaccine serotypes could increase in prevalence and reduce the benefits of vaccination; therefore, we examined non-PCV10 isolates recovered from meningitis during pre- (January 2008–May 2010) and post-vaccine (June 2010–December 2012) periods. Surveillance for pneumococcal meningitis was established at the Reference Hospital of Infectious Diseases in Salvador, Brazil. Serotypes were determined by multiplex PCR and/or Quellung reaction. Antimicrobial susceptibility testing was conducted by E-test and broth microdilution. Genotyping used PFGE and multi-locus sequence typing. A total of 148 cases of meningitis were identified from January 2008 to December 2012, 77 (52 %) of which were due to non-PCV10 isolates, with 50 (52.1 %) from pre-vaccine and 27 (52 %) from post-vaccine periods. In the post-vaccine period, the non-PCV10 serotypes 12F (n=6; 22.2 %), 10A (n=3; 11.1 %), 15B (n=2; 7.4 %) and 18B (n=2; 7.4 %) were the most prevalent. Forty-three isolates (55.8 %) were non-susceptible to one or more antibiotics. Non-susceptibility to penicillin was observed among serotypes 19A (three isolates), 9N (one isolate) and 12F (one isolate). PFGE and multi-locus sequence typing results demonstrated a wide genetic diversity among the isolates. During the early period following PCV10 introduction, no obvious emergence of a particular serotype was evident among non-PCV10 strains. This study underscores the importance of monitoring any changes among non-PCV10 cases after the introduction of PCV10.

**Songyin *et al.*, 2015.** Fifteen serotypes were identified among the 94 *S. pneumoniae* clinical isolates that were collected. Prevalent serotypes were 19F (42.6 %), 19A (8.5 %), 3 (8.5 %), and 6B (7.4 %). Potential immunization coverage rates for the 7-, 10- and 13-valent pneumococcal polysaccharide conjugate vaccines were 59.6, 62.6, and 79.6 %, respectively. Resistance rates to tetracycline, erythromycin, and trimethoprim/

sulfamethoxazole were 91.2, 80.2 and 63.8 %, respectively. Resistance rates to penicillin, amoxicillin, ceftriaxone, and cefotaxime were 47.3, 34.1, 19.8, and 18.7 %, respectively. In almost all cases, antimicrobial resistance of the *S. pneumoniae* isolates in patients five years or younger was higher than isolates collected from patients aged 51 years or older.

**Christina et al., 2015.** Only fifteen of 318 adult CF patients (5%) were ever found to have transient Pneumococcus colonization, and none developed persistent infection although length of carriage varied. As all isolates were stored, capsular serotyping could be performed using a multiplex PCR panel. Capsular serotyping revealed a varied distribution of several serotypes within these isolates. Lung function testing at time of incident Pneumococcus isolation was compared with values before and after isolation and showed no significant reduction in spirometry values, nor was there an increased need for rescue antibacterial therapy.

**Anis et al., 2015.** Fifty-nine *S. pneumoniae* were isolated from infection (n = 31) and colonization (n = 28) sites of patients (children and adults) attending the National Centre of Bone Marrow Transplantation. All isolates were characterized by serotype, antimicrobial resistance pattern and multilocus sequence typing (MLST). The majority (66.1%) of the isolates belonged to five serotypes all included in PCVs: 6B, 9V, 14, 19F and 23F. The potential coverage of the 10-valent and 13-valent PCV was of 71.2% and 76.3% respectively. Resistance rates were very high and 69.5% of the isolates were multidrug resistant: non-susceptibility rates to penicillin, amoxicillin and cefotaxime were 66.1%, 40.7% and 27.1%, respectively; resistance rates to erythromycin, clindamycin, tetracycline, chloramphenicol and trimethoprim-sulfamethoxazole, were 69.5%, 61.0%, 37.3%, 22.0% and 67.8%, respectively. The most frequent serotypes had STs characteristic of multidrug resistant international clones known to be highly successful and important causes of pneumococcal infection: Spain 23F-ST81, France 9V/14-ST156, Spain 6B-ST90, 19F-ST320, and Portugal 19F-ST177.

**Fen et al., 2015.** A total of 284 clinical pneumococcal isolates (270, 5, 4, 3, and 2 of which were isolated from sputum, bronchoalveolar lavage fluid, blood, cerebral spinal fluid, and ear secretions, respectively) from children less than 14 years of age who had not been vaccinated with a conjugate vaccine, were collected between January and December in 2013. All isolates were serotyped by multiplex polymerase chain reaction or quellung reactions and antimicrobial susceptibility testing was performed using the broth

microdilution method. The molecular epidemiology of *S. pneumoniae* was analyzed by multilocus sequence typing (MLST). Among the 284 pneumococcal isolates, 19F (33.5%), 19A (14.1%), 23F (12.0%), and 6A (8.8%) were the most common serotypes and the coverage rates of the 7-, 10-, and 13-valent pneumococcal conjugate vaccines (PCV7, PCV10, and PCV13) were 58.6%, 59.4% and 85.1%, respectively. Antimicrobial susceptibility showed that the prevalence rates of *S. pneumoniae* resistance to penicillin were 11.3% (32/284). Approximately 88.0% (250/284) of the isolates exhibited multi-drug resistance. MLST analysis revealed a high level of diversity, with 65 sequence types (STs) among 267 isolates. Specifically, the four predominant STs were ST271 (24.3%, 65/267), ST320 (11.2%, 30/267), ST81 (9.7%, 26/267), and ST3173 (5.2%, 14/267), which were mainly associated with serotypes 19F, 19A, 23F, and 6A, respectively.

**Elizeus et al., 2015.** In a population-based survey in April 2008, nasopharyngeal specimens were collected from 152 randomly selected healthy children under 5 years of age in the Iganga/Mayuge Health and Demographic Surveillance Site (HDSS). Medical history and prior treatment were recorded. Demographic characteristics and risk factors for carriage of resistant strains were obtained from the HDSS census. Bacteria were isolated and analysed for antibiotic susceptibility using disk diffusion and E test. *Streptococcus pneumoniae* carriage was 58.6%, and, while most (80.9%) isolates had intermediate resistance to penicillin, none was highly resistant. Whereas no isolate was resistant to erythromycin, 98.9% were resistant to trimethoprim-sulphamethoxazole (co-trimoxazole).

**Rapee et al., 2015.** Antibiotic resistance in *Streptococcus pneumoniae* is an emerging health problem worldwide. The incidence of antimicrobial-resistant *S. pneumoniae* is increasing, and nasal colonization of *S. pneumoniae* in children increases the risk of pneumococcal infection. In this study, the prevalence of *S. pneumoniae* nasal colonization was studied in Thai children from three different districts. *S. pneumoniae* nasal colonization was found in 38 of 237 subjects (16.0%). The carriage rate indicated higher rates in two rural districts (18.2% and 29.8%) than in the urban district (2.8%). The antibiotic susceptibility pattern was determined using the disk diffusion method. Prevalence of multi-drug resistance *S. pneumoniae* (MDR-SP) was 31.6%. Resistance to commonly prescribed antibiotics was found for ampicillin (5.3%), azithromycin (26.3%), cefepime (2.6%), chloramphenicol (18.4%), clindamycin (18.4%), erythromycin (21.1%),



oxacillin (44.7%), trimethoprim/sulfamethoxazole (78.9%) and tetracycline (15.8%). All isolates were sensitive to ceftriaxone. The pulsed-field gel electrophoresis pattern was used to compare genetic diversity of the *S. pneumoniae* isolates. PFGE demonstrated the variation in genotypes of *S. pneumoniae* from different areas. High prevalence of multi-drug resistance *S. pneumoniae* nasal colonization in healthy Thai children was indicated. Effective strategies for appropriate use of antibiotics are therefore needed in the community.

**Geng *et al.*, 2014** reported that, a total of 175 pneumococcal isolates were collected and all strains were resistant to erythromycin and clindamycin, about 39.4% strains were non-susceptible to penicillin G. Overall, 174 (99.4%) isolates were resistant to 3 types of antibiotics. Serotypes 19F (28.1%), 6B (19.7%), 19A (18.0%), and 23F (17.4%) were the most common serotypes in all identified strains. The serotypes coverage of PCV7 and PCV13 were 71.9% and 89.9%, respectively. Four international antibiotic-resistant clones, including Taiwan19F-14 (n=79), Spain23F-1 (n=25), Taiwan23F-15 (n=7) and Spain6B-2 (n=7), were identified. The Taiwan19F-14 clones have a higher non-susceptibility rate in b-lactams than other clones and non-clone isolates (p, 0.001). In addition, 98.7% Taiwan19F-14 clones were positive of ermB and mefA/E genes, compare to 33.3% in other clones and non-clone strains.

**Monica *et al.*, 2014.** We analysed the distribution of vaccine and non-vaccine *Streptococcus pneumoniae* serotypes and the antimicrobial susceptibility of pneumococcal strains isolated from healthy Romanian children. *S. pneumoniae* carriage was detected in 25.25% of the tested children. Carriage increased from 16.7% among infants to 29.4% in 3–5-year-old children (p < 0.0001). The proportions of the serotypes included in pneumococcal conjugate vaccines PCV7, PCV10, and PCV13 among our isolates were 39.9%, 40.1%, and 58.7%, respectively. Erythromycin resistance was 72.5%, and it was significantly lower in non-vaccine serotypes compared with PCV13 serotypes: 57.3% versus 83.6% (p < 10<sup>-7</sup>). Penicillin minimum inhibitory concentrations (MICs) >0.064 mg/l were recorded in 71.6%, but the penicillin MIC was >2 mg/l for only 8.4% of tested isolates.

**Aleksandra et al., 2013.** The prevalence of MRSP increased from 8% in 1998 to 22% in 2008 ( $P=0.0001$ ). MRSP were 51% *mef* (A) positive, 36% *erm* (B) positive, 8% dual *mef* (A) and *erm* (B) positive and 5% *mef* (A) and *erm* (B) negative. Dual *mef* (A)- and *erm* (B)-positive isolates increased in prevalence from 3% in 1998 to 19% in 2008 ( $P=0.001$ ). The prevalence of PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) decreased from 67% in 1998 to 31% in 2008 ( $P=0.0072$ ). The prevalence of serotype 19A, a non-PCV7 serotype, increased by 15% from 1998 to 2008; isolates of serotype 19A were MDR, dual *mef* (A) and *erm* (B) positive, genetically related by PFGE and associated with the presence of pili virulence factors.

**Eric et al, 2013.** This was a prospective cross-sectional study, and the subjects were children under 12 years old. Nasal swabs were collected from 50 children with HbSS disease and 50 children without HbSS disease. Nasopharyngeal swabs were collected from another group of 92 children with HbSS disease. The nasal and nasopharyngeal swabs were cultured for *S. aureus* and *S. pneumoniae*, respectively. Susceptibility testing was carried out on the *S. aureus* and *S. pneumoniae* isolates for various antibiotics, including penicillin, ampicillin, cefuroxime, erythromycin, cloxacillin, and cotrimoxazole. The carriage rates of *S. aureus* among pediatric subjects with HbSS disease and those without HbSS disease were 48% and 50%, respectively ( $P > 0.05$ ). *S. pneumoniae* carriage among the pediatric subjects with HbSS disease was 10%. Antibiotic resistance patterns of *S. aureus* carried by children with HbSS disease and children without HbSS disease were similar, and the *S. aureus* resistance rates were >40% for the various antibiotics, with the exception of erythromycin and cloxacillin. Low levels of *S. pneumoniae* resistance (0%–11%) were observed for the various antibiotics tested except cotrimoxazole, which showed an extremely high-percentage resistance (100%).

**Xiang et al., 2013.** A total of 89 strains were isolated and 87 isolates were included. The five prevailing serotypes were 19F (28.7%), 14 (16.1%), 23F (11.5%), 19A (9.2%) and 6B (6.9%). The most common sequence types (ST) were ST271 (21.8%), ST876 (18.4%), ST320 (8.0%) and ST81 (6.9%) which were mainly related to 19F, 14, 19A and 23F, respectively. The potential coverage by 7-, 10-, and 13-valent pneumococcal conjugate vaccine were 77.0%, 77.0%, and 89.7%, respectively. Among the 87 isolates investigated, 11.5% were resistant to penicillin, and for meningitis isolates, the resistance rate was 100%. Multi-drug resistance (MDR) was exhibited by 49 (56.3%) isolates. Eighty-four

isolates were resistance to erythromycin, among which, 56 (66.7%) carried the *ermB* gene alone and 28 (33.3%) expressed both the *ermB* and *mefA/E* genes.

**Susan *et al.*, 2013.** *Streptococcus pneumoniae* is a major cause of morbidity and mortality worldwide. Rates of carriage are highest in infants and the elderly. The objectives of this study were to determine the rate of nasopharyngeal colonization by *S. pneumoniae*, and to describe the antibiotic resistant patterns and the serotypes of the carried isolates. A cross-sectional study design was used. Nasopharyngeal swabs were collected from 315 children in the months of October and November 2010 and processed to isolate *S. pneumoniae*. The isolates were serotyped by the Quellung reaction and their antibiotic susceptibilities assessed by the disc diffusion method. The overall nasopharyngeal carriage rate for *S. pneumoniae* was 17%. Seventeen serotypes were detected amongst 55 strains analysed: 6A, 23F, 19F, 13, 6B, 14A, 20, 7C, 1, 15B, 35B, 19A, 11A, 34, 5, 3 and 23A. Susceptibility testing revealed that nearly all (98%) were resistant to cotrimoxazole, 9% were resistant to penicillin and 7% to cefotaxime. Resistance to chloramphenicol and erythromycin was 2% and 4%, respectively. All isolates were fully sensitive to tetracycline.

**Sabrina *et al.*, 2012.** This study aimed to determine the magnitude of nasopharyngeal carriage, antimicrobial resistance and serotype distribution of *Streptococcus pneumoniae* in healthy children under 5 years of age in Tanzania. Nasopharyngeal swabs were obtained from 300 healthy children attending a child health clinic at Muhimbili National Hospital in Dar es Salaam, Tanzania. *S. pneumoniae* was isolated and identified using conventional methods. Antimicrobial susceptibility testing was performed using the Kirby–Bauer disc diffusion method. Penicillin MICs and serotypes were determined by an agar gradient diffusion method and the Quellung reaction, respectively. A total of 105 samples (35.0%) were positive for *S. pneumoniae* and 115 serotypes were detected (ten specimens yielded two serotypes each). Overall, 78 of 115 isolates (67.8 %) were penicillin-nonsusceptible pneumococci (PNSP). The resistance levels of *S. pneumoniae* to trimethoprim– sulfamethoxazole, tetracycline, erythromycin, chloramphenicol and ceftriaxone were 82.6, 10.4, 6.0, 3.5 and 0.0 %, respectively. Multidrug resistance was detected in 19 isolates (16.5 %). The most prevalent serotypes were 19F (n525, 21.7 %), 6B (n515, 13.0 %), 9V (n514, 12.2 %) and 13 (n514, 12.2 %). Of the 64 pneumococcal isolates potentially covered by the seven-valent pneumococcal conjugate vaccine (PCV7),

44 (68.8 %) were PNSP. A high prevalence of PNSP, common pneumococcal serotypes circulating worldwide, was found, and many of the resistant pneumococci strains are covered by the PCV7. These findings indicate that the carriage rate of such resistant strains could be influenced by an appropriate vaccination programme in the study setting and by reinforcing regulations on the rational use of antimicrobial agents.

**Cristina *et al.*, 2011.** The study included 107 children. The most common serotypes were 14 (36.5%), 1 (16%), 5 (14.6%), 6B (6.3%) and 3 (4.2%). The proportion of identified serotypes contained in the heptavalent, 10-valent and 13-valent conjugate vaccines was 53.1, 86.5, and 96.9%, respectively. Pneumococcal strains were sensitive to penicillin (minimum inhibitory concentration, MIC  $\leq$  2  $\mu$ g/mL) in 100 cases (93.5%) and displayed intermediate resistance (MIC= 4  $\mu$ g/mL) in 7 cases (6.5%). No strains were penicillin-resistant (MIC  $\geq$  8  $\mu$ g/mL) according to the Clinical and Laboratory Standards Institute 2008 standards. Tested isolates were highly sensitive to vancomycin, rifampicin, ceftriaxone, clindamycin, erythromycin, and chloramphenicol.

**Semczuk *et al.*, 2010.** *Streptococcus pneumoniae* strains were isolated from children on admission to The Children's Memorial Health Institute, Warsaw, Poland between Jan 1999 and Dec 2007. A total of 784 isolates of *S. pneumoniae* were collected. Susceptibility to antibiotics was analyzed in two periods: 1999-2002 and 2003-2007. All the strains (185) collected in the first period originated from children with pneumococcal diseases. Of the 599 strains obtained in the second period, 234 were isolated from children with *S. pneumoniae* infection and 365 from children with nasopharyngeal carriage.

**Lian *et al.*, 2010.** A total of 171 *Streptococcus pneumoniae* isolates causing invasive disease were isolated from Chinese children. The serotype distribution and antimicrobial resistance were tested. The results suggested that the 7-valent pneumococcal conjugate vaccine has a preventive effect among children and that there should be long-term surveillance for serotype 19A.

**Kiran *et al.*, 2010.** There are reports of emergence of resistant strains of *S. pneumoniae* showing resistance to penicillin from all over the world, and now, resistance to multiple drugs (multidrug-resistant strains) has been added to it. However, scanty reports are available so far from India, depicting such resistance. Penicillin resistance was screened

by 1 µg oxacillin disk on Muller-Hinton blood agar followed by Minimum Inhibitory Concentration (MIC) detection by the agar dilution method according to the Clinical Laboratory Standards Institute (CLSI) guidelines. Antibiotic susceptibility for other antibiotics was carried out by the Kirby Bauer disk diffusion method followed by an E-test with HiComb test strips from Hi-media. Out of 50 isolates, 4% (95% Confidence Interval - 1.4, 9.4) showed total resistance to penicillin, whereas, 10% (95% CI; 1.6, 18.3) showed intermediate resistance. These penicillin-resistant pneumococci (4%) were also found to be multidrug-resistant (MDR) strains. Maximum resistance was observed for cotrimoxazole and tetracycline (24% each with 95% CI; 12.2, 35.8) followed by erythromycin and ciprofloxacin (14% each with 95% CI; 4.4, 23.6).

**Katherine et al., 2009.** We measured the burden of pneumococcal pneumonia by applying the proportion of pneumonia cases caused by *S. pneumoniae* derived from efficacy estimates from vaccine trials to WHO country-specific estimates of all-cause pneumonia cases and deaths. We also estimated burden of meningitis and non-pneumonia, non-meningitis invasive disease using disease incidence and case-fatality data from a systematic literature review. In 2000, about 14.5 million episodes of serious pneumococcal disease (uncertainty range 11.1–18.0 million) were estimated to occur. Pneumococcal disease caused about 826 000 deaths (582 000–926 000) in children aged 1–59 months, of which 91 000 (63 000–102 000) were in HIV-positive and 735 000 (519 000–825 000) in HIV-negative children. Of the deaths in HIV-negative children, over 61% (449 000 [316 000–501 000]) occurred in ten African and Asian countries.

**Merja et al., 2009.** Reported the 1007 pneumococci collected in 2002, 21.5%, 12.1%, and 14.4% were non-susceptible to erythromycin, penicillin and tetracycline, respectively. Multiresistance was detected in 10.5% of the isolates. Only 0.1% of the isolates were non-susceptible to ceftriaxone (non-meningitis breakpoint) and <1.5% to fluoroquinolones. Two isolates were nonsusceptible to linezolid. In 2002-2006, erythromycin resistance increased from 16% (2002) to 28% (2006) (Poisson regression,  $p < 0.0001$ ), penicillin non-susceptibility from 8% to 16% ( $< 0.0001$ ) and penicillin resistance from 0.8% to 3.7% ( $p = 0.03$ ). Tetracycline resistance remained stable (~10%), as did the proportion of multiresistant isolates (~5%). Levofloxacin and ceftriaxone resistance was rare. Serotypes 14, 9V, 6B, 19F and 19A were the most frequently non-susceptible to erythromycin or penicillin. In both sets of collections of pneumococci, the highest prevalence of erythromycin resistance was among isolates derived from 0- to 2-

year-old children: in 2006, 45.8% of isolates were resistant to erythromycin in this age group. In 2002, disk diffusion testing revealed 26/1007 (2.6%) pneumococcal isolates that produced one to several clearly visible colonies inside the growth inhibition zone, indicating heterogeneous resistance to telithromycin. The telithromycin MIC<sub>50</sub> and MIC<sub>90</sub> of these isolates were 2 and 4 mg/L (range 0.063 to 8 mg/L), respectively, when measured by the agar dilution method, but with CLSI broth microdilution in a normal atmosphere the MIC<sub>50</sub> and MIC<sub>90</sub> were 0.125 and 1 mg/L, respectively (range 0.063 – 2 mg/L). The telithromycin MIC<sub>50</sub> and MIC<sub>90</sub> of the zone isolates (isolated from the colony growing inside of the inhibition zone) was 32 mg/L and 64 mg/L, respectively, according to the agar dilution method in 5% CO<sub>2</sub>, whilst they were 4 and 8 mg/L with CLSI broth microdilution in ambient air. This type of telithromycin resistance has not previously been described. All such isolates were *erm* (B) positive and two of them also carried *mef* (E), but the exact underlying mechanism of telithromycin resistance remained unresolved. Telithromycin resistant isolates had seven distinct sequence types, of which ST193 was the most frequent (n = 19). Other sequence types were 133, 273, 271, 2248, 2306 and 2307. PFGE results were in accordance with the MLST results. ST193 isolates were all 19A serotype variants of the PMEN clone Greece21-30, while ST273 is a representative of the PMEN global clone Greece6B-22 and ST271 is a single locus variant of a multi-drug-resistant Taiwanese19F ST236 clone.

**Elina et al., 2008.** Pneumolysin-PCR in pleural fluid significantly improved the microbiologic diagnosis of empyema by increasing the detection rate of pneumococcus almost tenfold to that of pleural fluid culture (75 % vs. 8 %). In whole blood samples, PCR detected pneumococcus in only one child with pneumonia and one child with pneumococcal empyema. Sputum induction provided good-quality sputum specimens with high microbiologic yield. *Streptococcus pneumoniae* (46 %) and rhinovirus (29 %) were the most common microbes detected. The quantification results of the paired sputum and nasopharyngeal aspirate specimens provided support that the majority of the bacteria (79 %) and viruses (55 %) found in sputum originated from the lower airways. Pneumonia was detected in 14 % of children with influenza infection. A history of prolonged duration of fever, tachypnea, and pain on abdominal palpation were found to be independently significant predictors of empyema.

**Chinwendu et al., 2008.** Human immunodeficiency virus (HIV)-infected patients have an increased rate of pneumococcal infections. Within the HIV-infected population, patients with low CD4 cell counts have a higher rate of pneumococcal infection. The purpose of our study was to determine pneumococcal carriage and to examine the serotypes carried by HIV-infected patients after the introduction of the conjugate vaccine. Nasopharyngeal swabs were obtained from patients during routine clinic visits. Samples were cultured on blood agar plates with gentamicin and screened for alpha-hemolysis, optochin sensitivity, and bile solubility. Capsular serotypes were determined by multiplex PCR, multibead assay, or latex agglutination. Antibiotic susceptibility was determined by the Etest method. Multilocus sequence typing was also performed. Of the 175 patients enrolled, 120 patients had absolute CD4 cell counts above 200/mm<sup>3</sup> and 55 had counts below 200/mm<sup>3</sup>. A total of six (3.4%) patients carried pneumococci. All but one of these patients had received the 23-valent pneumococcal vaccine within the previous 5 years. Five of the isolates were serotypes that are not included in the 7-valent conjugate vaccine. Immunization with the pneumococcal polysaccharide vaccine does not prevent colonization in HIV-infected patients; however, the observation of carriage of serotypes not included in the conjugate vaccine may be due to herd immunity and serotype replacement effects in the general population.

**Ataiza et al., 2007.** A total of 232 pneumococcal strains were isolated, including 126 (54.31%) strains from male patients. Patients had an age range of 0 to 62 years and were distributed into four age groups: 0 to 5, 6 to 17, 18 to 50, and above 50. From the 36 distinct serotypes identified, eight were more prevalent: 14, 6B, 18C, 5, 19F, 23F, 9V, and 6A. The oxacillin test identified 67 penicillin-resistant strains, out of which 47 were confirmed by the E test as having intermediate level of resistance. None of the strains exhibited high-level resistance.

**Nao et al., 2006.** It was previously reported that two oligonucleotide primer sets (spn9802 and spn9828) for discriminating *Streptococcus pneumoniae* from pneumococcus-like oral streptococcal isolates using PCR had been developed. In this study, PCR amplification of the *lytA*, *ply*, *spn9802* and *spn9828* genes was used to identify presumptive *S. pneumoniae*. Two genetic groups were identified by analysing sputum samples from 28 patients with community-acquired pneumonia: the *lytA*-positive, *ply*-positive, *spn9802*-positive and *spn9828*-negative group, and the *lytA*-positive, *ply*-positive, *spn9802*-positive and *spn9828*-positive group. Isolates of the former group were resistant to

optochin, while those of the latter group showed susceptibility to optochin. The *lytA*-positive, *ply*-positive, *spn9802*-negative and *spn9828*-negative isolates, and *lytA*-positive, *ply*-positive, *spn9802*-negative and *spn9828*-positive isolates were not detected in sputum from patients with pneumonia. Subsequently, a total of 92 saliva samples from healthy individuals was screened by PCR using these primer sets. The *lytA*-positive, *ply*-positive, *spn9802*-positive and *spn9828*-negative group was identified more frequently in saliva from healthy children than in saliva from older healthy individuals and patients with pneumonia. The *lytA*-positive, *ply*-positive, *spn9802*-positive and *spn9828*-positive group was found frequently in saliva from healthy children, and in saliva and sputum from patients with pneumonia. This study demonstrates a rapid, optimal screening method for the genotypic identification of presumptive *S. pneumoniae* by PCR using four genes highly specific for *S. pneumoniae*.

**Jill et al., 2003.** Twenty-nine cases of SPIN were identified from a total of 4428 episodes of *S. pneumoniae* infection in children. Sixty-six percent were male, and 55% were white; the mean age was 18.1 day ( $\pm 8.2$ ). Ninety percent of infants were  $>38$  weeks' gestation. Two mothers had bacterial infections at delivery; 1 had *S. pneumoniae* isolated from both blood and cervix, and 1 had clinical amnionitis. The primary diagnoses in the neonates were bacteremia (8), meningitis (8), bacteremic pneumonia (4), septic arthritis/osteomyelitis (1), and otitis media (8). Thirty percent of infants with invasive SPIN presented with leukopenia/neutropenia, but this did not predict poor outcome. The infecting pneumococcal serogroups were 19 (32%); 9 (18%); 3 and 18 (11% each); 1, 6, and 14 (7% each); and 5 and 12 (3.5% each). Twenty-six percent of invasive neonatal infections were caused by serogroups 1, 3, 5, and 12, which are not contained in the heptavalent pneumococcal vaccine. In contrast, 6% of invasive nonneonatal disease was caused by these same nonvaccine serogroups. Susceptibility testing demonstrated that 21.4% of isolates were penicillin nonsusceptible and 3.6% were ceftriaxone nonsusceptible. Three (14.3%) neonates with invasive SPIN died; all deaths occurred within 36 hours of presentation. Deaths did not appear to be related to pneumococcal serogroup or susceptibilities.

**Jorg et al., 2003.** Previous antibiotic exposure is one of the most important predictors for acquisition of penicillin-nonsusceptible *Streptococcus pneumoniae* infection. To determine the impact of duration of exposure to different antibiotic classes, a study of 303 patients with *S. pneumoniae* bacteremia was undertaken. Ninety-eight cases of bacteremia



(32%) were caused by a penicillin-nonsusceptible isolate. Bivariate analysis revealed that use of  $\beta$ -lactams, sulfonamides, and macrolides within the last 1 and 6 months before presentation was associated with PNSP bacteremia ( $P < .05$ ). Fluoroquinolone consumption was not related to bacteremia due to PNSP ( $P > .1$ ). Both short- and long-term  $\beta$ -lactam use significantly increased the risk for PNSP infection. Logistic regression analysis revealed that use of  $\beta$ -lactams and macrolides in the 6 months before the first positive blood culture result were independent risk factors ( $P < .05$ ). Risk for acquiring PNSP infection depends on both the class of antibiotic to which the patient was exposed and the duration of therapy.

**Joaquim et al., 2002.** Reported the use of new diagnostic methods such as immunological techniques and polymerase chain reaction has proven invaluable for specific diagnosis and epidemiological investigation, showing adequate sensitivity, specificity and promptness of results, with the aim of guiding therapy properly. Review of epidemiological studies of community-acquired pneumonia showed that *Streptococcus pneumoniae* is still one of the most significant etiologic agents in all age groups, in developing and industrialized countries. Resistance of this agent to penicillin and cephalosporins is increasing in all continents and is worrisome. Atypical agents such as *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* are common in community-acquired pneumonia, mainly in children older than 4 years, representing one third of the cases in industrial countries. However, their prevalence in developing countries remains to be determined. Respiratory syncytial virus is also a very common etiology of community acquired pneumonia and may cause severe infections, mainly in infants and younger children. The introduction of new conjugated vaccines for *Streptococcus pneumoniae* and *Haemophilus influenzae* type b resulted in significant reduction of morbidity and mortality of pneumonia in children.

**Susan et al., 2001.** Resistance to penicillin and multiple antimicrobial agents among *Streptococcus pneumoniae* strains is becoming an increasing problem worldwide and in Asia. To determine the prevalence of carriage of *S. pneumoniae* isolates not susceptible to penicillin in young children, we obtained nasopharyngeal swab specimens from 1,978 children (ages, 2 to 6 years) attending 79 day care centers or kindergartens. Three hundred eighty-three strains of *S. pneumoniae* were isolated from these children. Fifty-eight percent of these isolates had reduced susceptibility to penicillin, 123 (32.1%) were intermediate, and 100 (26.1%) were resistant. A very high penicillin MIC (4 g/ml) was

found in 3.3% of the isolates. The isolates also demonstrated high rates of resistance to other antimicrobial agents (51.2% to cefaclor, 50.2% to cefuroxime, 42.8% to cefotaxime, 80.7% to trimethoprim-sulfamethoxazole, 77% to erythromycin, 60% to clindamycin, and 33.7% to chloramphenicol). No isolate was resistant to fluoroquinolone. Multidrug resistance (not susceptible to the -lactams and three or more other classes) was found in 39.4% of the isolates. Risk factors for the carriage of *S. pneumoniae* not susceptible to penicillin were multiple physician visits in the preceding 3 months and use of antimicrobial agents by the individual or by household members in the preceding 3 months. In the logistic regression analysis, only the use of antimicrobial agents in the preceding 3 months was an independent risk factor (P 0.004; odds ratio, 2; 95% confidence interval, 1.2 to 3.2). This study demonstrated the high prevalence of antibiotic-resistant *S. pneumoniae* in healthy young children in the community in Hong Kong.

**Matthew *et al.*, 2001.** In April 1998, surveillance nasopharyngeal cultures were obtained from 368 children aged <8 years in community A and 369 children in community B. The number of antibiotic courses per child within 1 year before culture was higher in community B than A (mean 2.2 vs 1.7). Conversely, oral cephalosporins were more frequently used in community A than B (community A: 22% received cephalosporins within 4 months; community B: 12%). Colonization with *S. pneumoniae* was detected in 24% of children in community A and 14% in community B; 36% of isolates from community A and 28% of isolates from community B were resistant or intermediately susceptible to at least 1 antibiotic tested. Reduced susceptibility was most common to trimethoprim-sulfamethoxazole and cefaclor (28% and 26%, respectively). Pneumococcal carriage (susceptible or resistant) was independently associated with age <5 years (odds ratio [OR]: 2.2), childcare exposure (OR: 2.4), presence of a sibling with a positive culture (OR: 3.3), and residence in community A (OR: 1.7). Among carriers, age <2 years (OR: 2.6), use of cephalosporins within the preceding 4 months (OR: 2.7), and having a sibling colonized with resistant *S. pneumoniae* (OR: 5.5) were independent predictors of reduced susceptibility or resistance. Each pair of resistant isolates from siblings was indistinguishable by pulsed field gel electrophoresis and other molecular typing techniques. Several pneumococcal isolates from these isolated rural areas had the molecular characteristics of international clones of multiple-drug-resistant pneumococci that have been associated with worldwide spread.

**Nasrin et al., 1999.** A total of 461 nasal swabs were collected and *S. pneumoniae* was isolated from 171 (37.1%). Penicillin resistance was found in 12.3% of these isolates, with high-level resistance in 0.6%. Resistance rates were higher for cotrimoxazole (44.4%) and erythromycin (18.1%) than for penicillin. Multidrug resistance was found in 19% of these isolates. There was a significant association between the attendance at a day care centre and carriage of pneumococcal (53% vs 32%, odds ratio (OR) 2.4, 95% confidence interval (CI) 1.5–3.7,  $P < 0.001$ ). Children who attended day care centres and had received anti-biotics during the 4 months prior to swab collection were three times more likely to carry an antibiotic-resistant isolate than children who had neither attended a day care centre nor received antibiotics (68% vs 40%, OR 3.1, 95% CI 1.2–8.4,  $P = 0.02$ ).

**Aura et al., 1997.** *Streptococcus pneumoniae* is one of the principal causal agents of acute respiratory infection (ARI) in children, and its resistance to antibiotics has increased worldwide. This study examined the patterns of susceptibility to antibiotics of *S. pneumoniae* that had colonized the upper respiratory tract of 272 children hospitalized for pneumonia in two hospitals in Santafe de Bogota. *S. pneumoniae* was isolated from 114 patients (42%). Diminished susceptibility to penicillin was noted in 19 isolates (17%), with 12 (11%) having an intermediate level of sensitivity and 7 (6%) showing outright resistance. Only 1 of the 19 isolates resistant to penicillin also showed resistance to ceftriaxone. There was diminished sensitivity to erythromycin in 3 isolates (3%), to chloramphenicol in 6 (5%), and to co-trimoxazole (trimethoprim + sulfamethoxazole) in 46 (40%). Resistance to multiple drugs was found in 7 isolates (6%). The most commonly encountered penicillin resistant serotype was 23F (68.4%). An association was observed between age, prior use of antibiotics, and colonization by *S. pneumoniae* with reduced penicillin sensitivity or multiple-drug resistance. This study confirmed the presence of antibiotic-resistant *S. pneumoniae* in Colombia and highlights the importance of the rational use of antibiotics and of the implementation of epidemiologic surveillance for this agent.

**Vilhjalmur et al, 1996.** Total antimicrobial sales for children (6223 prescriptions) among the four areas for which data were available ranged from 9.6 to 23.2 defined daily doses per 1000 children daily (1.1 to 2.6 courses yearly per child). Children under 2 consumed twice as much as 2-6 year olds (20.5 v 10.9 defined daily doses per 1000 children daily). Nasopharyngeal specimens were obtained from 919 children, representing 15-38% of the

peer population groups in the different areas. Pneumococci were carried by 484 (52.7%) of the children, 47 (9.7%) of the isolates being resistant to penicillin or multiresistant. By multivariate analysis age (<2 years), area (highest antimicrobial consumption), and individual use of antimicrobials significantly influenced the odds of carrying penicillin resistant pneumococci. By univariate analysis, recent antimicrobial use (two to seven weeks) and use of co-trimoxazole were also significantly associated with carriage of penicillin resistant pneumococci.

## **CHAPTER III**

### **MATERIALS AND METHODS**

#### **3.1 Study design**

A cross-sectional study design was employed. Blood & Nasopharyngeal swab samples of pneumonia patients were collected at different intervals during the study period.

#### **3.2 Study area and period**

This study was conducted from January-November 2018 at different hospitals of Dinajpur district of Bangladesh. All microbiological analysis was carried out in microbiology laboratory of Hajee Mohammad Danesh Science and Technology University (HSTU), Dinajpur.

The samples were collected from three main hospitals of Dinajpur district that includes: M Abdur Rahim Medical College Hospital, Dinajpur, Aurobindo Shishu Hospital, Dinajpur & Islami Bank Community Hospital, Dinajpur.




**Plate No. 1. Sample Collection**

### **3.3 Collection of Sample**

40 samples were collected from three hospitals of Dinajpur district. Out of 40 samples, 20 samples were collected from M. Abdur Rahim Medical College Hospital. 15 samples were collected from Arobindo Shishu Hospital of Dinajpur & the rest of 5 samples were collected from Islami Bank Community Hospital, Dinajpur (IBCH).

### **3.4 Experimental Layout**

The present study was conducted into three phases; in first phase, samples were collected by different age of pneumonia patients & hospital and age of the patients were selected. In the second phase isolation and identification of the organisms from the collected sample using cultural, staining, biochemical & molecular characterization was done. In third phase drug resistant pattern of the selected isolates were determined by using different antibiotic discs available in the market. The experimental layout of the present study is shown in figure:



**Plate No. 2: The schematic illustration of the experimental layout**

### 3.5 Sample processing, isolation and identification of bacteria

All samples that were collected from different hospitals of Dinajpur district were transported to the microbiological laboratory of department of Microbiology, HSTU, in cool conditions and processed within two hours of collection. To determine the total viable plate count, serial 10-fold dilutions of samples were prepared in physiological saline, and 0.5 mL aliquot was spread plated on plate count agar (PCA). Plates were incubated for 24 hours at 37°C before bacteriological counts were done.

The number of colonies on each plate having 30–300 colonies was counted by using a digital colony counter. Finally, the bacterial count was reported CFU/mL as follows:

$$CFU/mL = \frac{\text{Colonies counted} \times \text{Dilution factor}}{\text{Actual volume of sample in plate, mL}}$$

After that, based on colony morphology representative colonies were picked and sub-cultured on differential media such as blood agar. After obtaining pure colonies and recording important features such as hemolysis on blood agar isolated organisms were identified biochemically in a systematic way following standard methods (Holt JG *et.al.*)

### 3.6. Bacteriological Media

#### 3.6.1 Media used in the Experiment

##### 3.6.1.1 Solid Media

###### 1. Plate Count Agar

Plate Count Agar (PCA), also called Standard Methods Agar (SMA), is a microbiological growth medium commonly used to assess or to monitor "total" or viable bacterial growth of a sample. PCA is not a selective medium (Cheesbrough, 1985).

###### 2. Nutrient Agar Medium (HI-MEDIA, India)

Nutrient agar is a basic media that is used for cultivating of non-fastidious microorganisms (Cheesbrough, 1985).



### **3. Blood Agar Medium (HI-MEDIA, India)**

For the isolation, cultivation and detection of hemolytic reaction of fastidious microorganisms. Blood Agar Base is suitable to isolate and cultivate a wide range of microorganisms with difficult growth. Upon adding blood, it can be utilized for determining hemolytic reactions *Streptococcus pneumoniae* gives alpha hemolysis. *Streptococcus pyogenes* gives beta hemolysis (Clin. Path 1951).

#### **3.6.1.2 Liquid Media**

- Nutrient broth (Difco)
- Methyl Red-Voges Proskauer (MR-VP) broth (Difco)
- 1% Pepton Water (Difco)
- Motility Indole Urease Broth (Difco)
- Buffered peptone water Broth

#### **3.6.2. Reagent**

- Crystal violet dye
- Grams iodine
- Alcohol
- Safranin
- Saline
- Iodine solution
- Kovac's reagent
- Methyl- red solution
- 3% H<sub>2</sub>O<sub>2</sub>
- P –Amino dimethylanilin oxalate
- Phenol red
- Phosphate buffered saline (PBS) solution
- 10% sodium deoxycholate (Bile salt) solution.

### 3.7 Materials used for bacterial genomic DNA isolation

- TE buffer
- 10% (w/v) Sodium dodecyl sulfate (SDS)
- 20 mg/ml proteinase k (stored in small single-use aliquots at -20 °C)
- 3 M Sodium Acetate, pH 5.2
- 25:24:1 Phenol/Chloroform/Isoamyl alcohol
- Isopropanol
- 70% Ethanol
- 95% Ethanol
- 1.5 ml Microcentrifuge tubes

#### 3.7.1 Materials used for Polymerase Chain Reaction

**Table 1: PCR Reaction Mixture for 16s rRNA**

|                        |         |
|------------------------|---------|
| Buffer                 | 2.5 µl  |
| dNTP                   | 2.5 µl  |
| MgCl <sub>2</sub>      | 2.5 µl  |
| Forward Primer (27F)   | 1.0 µl  |
| Reverse Primer (1492R) | 1.0 µl  |
| Nano Pure Water        | 12.5 µl |
| DNA                    | 2.0 µl  |
| Taq DNA Polymerase     | 1.0 µl  |
| Final Volume           | 25 µl   |

- Primers used for PCR :
  - 16S rRNA gene region was amplified with the universal primers.
    - Forward primer- 27F (5' AGAGTTTGATCCTGGCTCAG 3')
    - Reverse primer- 1492R (5' TACCTTGTTACGACTT 3')
- Thermal Cycler (Thermo cycler, ASTEC, Japan)
- 2% Agarose gel
- Gel casting tray with gel comb
- TAE buffer
- Microwave oven
- Conical flask

- Electrophoresis apparatus (Biometra standard power pack P 2T)
- 100 bp DNA size marker
- Bromphenicol blue of loading buffer
- Ethidium bromide (0.5 µl/ml)
- Distilled water
- UV trans-illuminator

### **3.8 Glassware and Appliances**

The different types of important equipment used for this work are listed in following: Distilled water, Sterile bent glass or plastic spreader rods, Micropipette (5-50µl; 10-100µl; 50-500µl; 100-1000µl), Freeze (-20°C), Refrigerator (4°C), Spirit lamp, Vortex Mixture, Labeling tape, Experimental test tube, Stopper, Petri dish, Conical flask, Durham's tube, Slide, Microscope, Cotton, Immersion Oil, Autoclave, Thermometer, Incubator, Jar, Beaker, Cylinder, Electric Balance, Filter paper, Bacteriological loop etc.

### **3.9 Morphological Characterization of Bacteria by Gram's Staining Method**

The most widely used staining procedure in microbiology is the gram stain ,discovered by the Danish scientist and physician Hans Christian Joachim Gram in 1884, Gram staining is a differential staining technique that differentiates bacteria into two groups: gram-positives and gram-negatives. The procedure is based on the ability of microorganisms to retain color of the stains used during the gram stain reaction. Gram-negative bacteria are decolorized by the alcohol, losing the color of the primary stain, purple. Gram-positive bacteria are not decolorized by alcohol and will remain as purple. After decolorization step and a counterstain is used to impart a pink color to the decolorized gram- negative organisms.

### **3.10 Preparation of Gram's staining solution**

The four solutions:

- Crystal violet
- Gram's iodine
- 95% Alcohol
- Safranin (Counterstain).

### **3.10.1 Gram staining procedure**

1. Clean glass slides were taken.
2. A sterile technique was used, a smears of each of the organisms was prepared. Smear made of a drop of water on the slide was placed then each organism separately to the drop water with a sterile was transferred. A circular motion of the inoculating loop of organism was mixed and spreads.
3. Air-dry the smears were allowed then heat-fixed in the usual manner.
4. Smears were flooded with crystal violet and let stood for 1 min then slides were washed with tap water.
5. Smears were flooded with grams iodine mordant and let stood for 1 min. Slides were washed with tap water.
6. Smears were decolorized with 95% ethyl alcohol. Slides were washed with tap water.
7. Smears were counter stain with safranin for 30 sec. Slides were washed with tap water.
8. Slides were examined under oil immersion. (James G. Cuppuccion, Natalie Sherman, 1996).

### **3.11 Biochemical Tests**

Isolated organism with supporting growth characteristics of suspect identified by biochemical tests. Several types of biochemical tests were performed in this study to confirm the specific bacteria that are as follows:

1. Catalase Test
2. Indole Test
3. Methyl Red (MR) Test
4. Voges Proskauer (VP) Test
5. Lactose Fermentation Test
6. Triple Sugar Iron (TSI) Test
7. Bile Solubility Test

### **3.11.1 Catalase Test**

This test was used to differentiate bacteria which produce the enzyme catalase. To perform this test, a small colony of good growth pure culture of test organism was smeared on a slide. Then one drop of catalase reagent (3% H<sub>2</sub>O<sub>2</sub>) was added on the smear. The slide was observed for bubbles formation. Formation of bubble within few seconds was the indication of positive test while the absence of bubble formation indicated negative result (Cheesbrough, 1985).

### **3.11.2 Indole Test**

Two milliliter of peptone water was inoculated with the 5 ml of bacterial culture and incubated at 37°C for 48 hours. Kovac's reagents (0.5ml) were added, shake well and examined after 1 minute. A red color in the reagent layer indicated indole test positive. In negative case there is no development of red color (Cheesbrough, 1985).

### **3.11.3 Methyl Red Test (MR)**

Sterile MR-VP broth was inoculated with the test organism and following incubation at 37°C for 24 hours. if the organism would ferment glucose via the mixed acid fermentation pathway like lactic, acetic, which decreases the PH , hence upon the addition of the indicator methyl red the broth becomes red in color and yellow color indicated a negative result (Cheesbrough, 1985).

### **3.11.4 Voges-Proskauer Test (VP)**

Voges Proskauer Test – If the organism would ferment glucose via the butylenes glycol pathway, an intermediate product, acetyl methyl carbinol or acetone which is neutral is converted to diacetyl upon the addition of the VP – Reagent –B (40% KOH with 0.3% creatine) in the presence of VP – Reagent – A (5% alpha- naphthol in abs. methyl alcohol). Diacetyl is red in color. Negative is yellow color (Cheesbrough, 1985).

### **3.11.5 Triple Sugar Iron (TSI) Test**

This tube medium is used to identify Gram-negative enteric bacilli based on the following biochemical characteristics (Cheesbrough, 1985)

- Glucose fermentation – indicated by yellow butt
- Lactose fermentation – indicated by yellow slant

- Hydrogen sulfide production – indicated by blackening of the medium
- Gas production – indicated by presence of a crack, bubble or gas space
- pH indicator – phenol red
- Hydrogen sulfide indicator – ferric ammonium citrate with sodium thiosulfate.

### **3.11.6 Bile Solubility Test**

Bile Solubility Test is the test, which differentiate *Streptococcus pneumoniae* (positive-soluble) from alpha-hemolytic streptococci (negative- insoluble). *Streptococcus pneumoniae* is bile soluble whereas all other alpha-hemolytic streptococci are bile resistant. *S. pneumoniae* has an autolytic enzyme, which can be demonstrated by allowing a broth culture to age in the incubator; at 24 hours, the broth is turbid; after a few days, the medium will become clear. Bile or a solution of a bile salt (e.g., sodium desoxycholate) rapidly lyses pneumococcal colonies. Lysis depends on the presence of an intracellular autolytic enzyme, amidase. Bile salts lower the surface tension between the bacterial cell membrane and the medium, thus accelerating the organism's natural autolytic process. Bile salts activate the autolytic enzyme, which induces clearing of the culture (Cheesbrough, 1985).

#### **3.11.6.1 Reagents for Bile Solubility Test**

10% sodium deoxycholate (bile salt) solution

- Dissolve 10 gram of sodium deoxycholate into 100 ml sterile distilled water.

### **3.12 Antibiotic susceptibility testing**

Once the bacteria is isolated and identified from each sample collected, the standard Kirby-Bauer disk diffusion method was used to determine the antimicrobial susceptibility profiles of the isolates according to the recommendations of National Committee for Clinical Laboratory Standards (CLSI 2013).

Bacterial inoculum was prepared by suspending the freshly grown bacteria in 4–5 ml sterile nutrient broth and the turbidity was adjusted to that of a 0.5 McFarland standard.

The antimicrobial susceptibility testing was performed using Mueller-Hinton medium, Antibiotic disks were applied using a sterile forceps. Agar plates were incubated at 37°C for 18 hours.

After overnight incubation at 37 °C, the diameter in millimeters of the zones of inhibition around each of the antimicrobial discs was recorded and categorized as resistant or sensitive in accordance with company recommendations. All isolates were tested for sensitivities to 10 of routine and practical antibiotics.

### 3.12.1 Antimicrobial agents with their disc concentration

| Sl. No | Antimicrobial agents | Symbol | Disc concentration (µg/disc) | Diameter of zone of inhibition (ZOI) |              |             |
|--------|----------------------|--------|------------------------------|--------------------------------------|--------------|-------------|
|        |                      |        |                              | Resistant                            | Intermediate | Susceptible |
| 1      | Penicillin           | P      | 10                           | ≤ 11                                 | 12-21        | ≥ 22        |
| 2      | Ampicillin           | AMP    | 25                           | ≤ 13                                 | 14-16        | ≥ 17        |
| 3      | Amoxicillin          | AM     | 30                           | ≤ 13                                 | 14-17        | ≥ 18        |
| 4      | Amikacin             | AK     | 30                           | ≤ 14                                 | 15-16        | ≥ 17        |
| 5      | Cephalexin           | CN     | 30                           | ≤ 14                                 | -            | ≥ 14        |
| 6      | Ciprofloxacin        | CIP    | 5                            | ≤ 20                                 | 21-30        | ≥ 31        |
| 7      | Gentamycin           | GEN    | 10                           | ≤ 12                                 | 13-14        | ≥ 15        |
| 8      | Kanamycin            | K      | 30                           | ≤ 13                                 | 14-17        | ≥ 18        |
| 9      | Erythromycin         | E      | 15                           | ≤ 13                                 | 14-17        | ≥ 18        |
| 10     | Azithromycin         | AZM    | 10                           | ≤ 13                                 | 14-17        | ≥ 18        |
| 11     | Neomycin             | N      | 30                           | ≤ 12                                 | 13-16        | ≥ 17        |
| 12     | Vancomycin           | VA     | 30                           | ≤ 9                                  | 10-11        | ≥ 12        |
| 13     | Streptomycin         | S      | 10                           | ≤ 11                                 | 12-14        | ≤ 15        |
| 14     | Bacitracin           | B      | 10                           | ≤ 8                                  | 9-12         | ≤ 13        |

Source: CLSI- 2013 [Note: S=Sensitive, R=Resistant, I=Intermediate]

### 3.13 Maintenance of stock culture by sterile buffered glycerin method

After the experiment it was necessary to preserve the isolated organisms for longer periods. For this purpose, pure culture of at least one organism per isolates were stored in sterilized 80% glycerin and used as stock culture. The equal volume of 80% glycerin and bacterial culture were mixed and sealed with paraffin wax and stored at 37° c. The isolated organisms were given code name for convenience. (Buxton and Fraser, 1977).

### **3.14 Laboratory Preparation**

All items of glassware including test tubes, pipettes, cylinders, flasks conical flasks, glass plates, slides, vials and other necessary instruments cleaned by detergents powders. The glassware then cleaned by brushing, washed thoroughly and finally sterilized by autoclaving for 15 minutes at 121°c under 15 lbs. pressure per square inch. Autoclaved items were kept in oven at 50°C for further use.

### **3.15 Preparation of Culture Media**

#### **3.15.1 Solid Media**

##### **3.15.1.1 Plate count agar (PCA)**

17.5g added to 1 litre of distilled water. Dissolved by bringing to the boil with frequent stirring, then mixed & distributed into final containers. Sterilized by autoclaving at 121°C for 15 minutes. After autoclaving, the medium was poured into sterile petri dishes & allowed to solidify. After solidification of the medium in the petri dishes, these were incubated at 37°C overnight to check their sterility & used for cultural characterization or stored at 4°C for further use (Cater, 1979).

##### **3.15.1.2 Nutrient agar Media**

28 grams of nutrient agar was suspended in 1000 ml of cold distilled water in a flask and heated to boiling for dissolving the medium completely (necessary calculation was done for required number of plates).The medium was then sterilized by autoclaving sterilized by autoclaving for 15 minutes at 121°c under 15 lbs. pressure per square inch. After autoclaving, the medium was poured into each sterilized petri dishes and allowed to solidify. After solidification all petri dishes was incubated at 37°c for overnight to check their sterility and used for cultural characterization (Cater, 1979).

##### **3.15.1.3 TSI Slant**

65 grams TSI agar base powder was mixed in 1000 ml of cold distilled water in a flask and mixed thoroughly, then heated to boiling for dissolving the medium completely (necessary calculation was done for required number of test tubes).The medium was then sterilized by autoclaving for 15 minutes at 121°c maintaining a pressure of 1.2 kg/.Then 20/10 ml of medium was poured into each sterilized test tubes and allowed to cool and to



solidify (kept in horizontal position). After solidification test tube were used for biochemical characterization and incubated at 37° c for 24 hours (Cater, 1979).

#### **3.15.1.4 Blood Agar**

40 gams of Blood agar base (HI-MEDIA, India) powder was dissolved in 1000ml of distilled water. The medium was sterilized by autoclaving at 1.2 kg/cm<sup>2</sup> Pressure & 121°C for 15 minutes & 45°C. Then 5-10% sterile defibrinated blood was added to the medium and distributed to sterile Petridishes and allowed to solidify. After solidification of the medium in the petridishes, these were incubated at 37°C for overnight to check their sterility and used for cultural characteriation or stored at 4°C refrigerator for future use. (Cater, 1979).

#### **3.15.2 Liquid Media**

##### **3.15.2.1 Nutrient Broth**

13 grams of nutrient broth was suspended in 1000 ml of cold distilled water in a flask and heated to boiling for dissolving the medium completely(necessary calculation was done for required number of plates). The solution is then distributed in test tubes, stoppered with cotton plugs and sterilized in the autoclave machine at 121° c and 15 pounds pressure per square inch for 15 minutes. The sterility of the medium was checked by incubating overnight at 37° c and used for general cultural medium (Cater, 1979).

##### **3.15.2.2 Methyl red- Voges Proskauer (MR-VP) Broth**

17 grams of MR-VP medium was suspended in 1000 ml of cold distilled water in a flask and heated to boiling for dissolving the medium completely(necessary calculation was done for required number of plates). The solution is then distributed in test tubes, stoppered with cotton plugs and sterilized in the autoclave machine at 121° c and 15 pounds pressure per square inch for 15 minutes. The sterility of the medium was checked by incubating overnight at 37° c and used for biochemical characterization (Cater, 1979).

### **3.16 Preparation of Reagents**

#### **3.16.1 Methyl red solution**

The indicator MR solution was prepared by dissolving 0.05 gram of Bacto methyl-red in 28ml of 95% alcohol and diluted to 22 ml with addition of distilled water (Merechant and Packer, 1967).

#### **3.16.2 Alpha- Naphthol solution**

Alpha- Naphthol solution was prepared by dissolving 5 gram of 1-Naphthol in 100 ml of 95% ethyl alcohol (Merechant and Packer, 1967).

#### **3.16.3 Kovac's Reagent**

The solution was prepared by mixing 25 ml of concentrated Hydrochloric Acid in 75 ml of Amyl alcohol and to this mixture 5 grams of paradimethyl –aminobenzyldehyde crystals were added. This was then kept in a flask equipped with rubber cork for future use (Merechant and Packer, 1967).

#### **3.16.4 Potassium hydroxide solution**

To prepare 40% KOH solutions add 4gm KOH solids with 100 ml distilled water (Merechant and Packer, 1967).

#### **3.16.5 Phosphate buffered Saline Solution**

For preparation of phosphate (PBS) solution, 8 grams of sodium chloride, 2.89 gram of disodium hydrogen phosphate disodium hydrogen phosphate, 0.2 gram of potassium chloride and 0.2 gram of potassium hydrogen phosphate were suspended in 1000 ml of distilled water. The solution was heated to dissolve completely. The solution was then sterilized by autoclave at 121° maintaining a pressure of 15 pounds per square inch for 15 minutes and stored at refrigerator until use. The p<sup>H</sup> of the solution was measured by a p<sup>H</sup> meter and maintained at 7.0-7.2 p<sup>H</sup> (Cheesbrough 1994).

### 3.17 PCR Amplification, Sequencing of 16S rRNA Genes with Universal Primers and Phylogenetic Analysis of *Streptococcus pneumoniae*

#### 3.17.1 Basic protocol of bacterial genomic DNA isolation

Bacteria from saturated liquid culture are lysed and proteins are removed by digestion with proteinase-k. Cell wall debris, polysaccharides and remaining proteins are removed by Phenol-chloroform extraction and high-molecular-weight DNA is recovered from the resulting supernatant by isopropanol precipitation.

##### Procedure

- A 25 ml of liquid culture was inoculated with *Streptococcus pneumoniae*.
- 1.0 ml of the overnight culture was allowed to spin in a microcentrifuge tube for 5 minutes at 10000 rpm.
- The supernatant was discarded.
- This step was repeated.
- The pellet was re-suspended in 467  $\mu$ l TE buffer by repeated pipetting. 30  $\mu$ l of 10% SDS & 3  $\mu$ l of 20 mg/ml Proteinase-k to give a final concentration of 100  $\mu$ l/mg Proteinase-k in 0.5% SDS. Thoroughly mixed & incubated 30 min for 1 hr at 37°C.
- Approximately equal volume (500  $\mu$ l) of Phenol/Chloroform/Isoamyl alcohol was added. Mixed thoroughly but very gently to avoid shearing the DNA, by inverting the tube until the phase are completely mixed.
- Then the tubes were centrifuged at 12000 rpm for 10 minutes.
- The aqueous & viscous supernatant (~400  $\mu$ l) were removed to a fresh microcentrifuge tube, leaving the interface behind. An equal volume of Phenol/Chloroform/ Isoamyl alcohol extract were added thoroughly mixed & allowed to spin in a microcentrifuge at 10000 rpm for 5 min.
- The supernatant was transferred to a fresh tube.
- 1/10th volume of 3M sodium acetate was added & mixed well.
- 0.6 volume of isopropanol was added to precipitate the nucleic acids & kept on ice for 10 minutes.
- Centrifuged at 13500 rpm for 15 minutes.
- The supernatant was discarded.

- The obtained pellet was washed with 1 ml of 95% ethanol for 5 minutes. Then centrifuged at 12000 rpm for 10 minutes.
- The supernatant was discarded.
- The pellets was dried as there is no alcohol.
- The pellet was re-suspended 50  $\mu$ l of TE & then 7.5  $\mu$ l of RNase. The DNA was stored at 4 °C for short term and at -20 °C for long term.

### 3.17.2 PCR amplification & sequencing of 16S rRNA

#### Condition of PCR:

**Table 2: Condition of PCR**

| Step                 | Temperature | Duration | Cycles |
|----------------------|-------------|----------|--------|
| Initial denaturation | 95 °C       | 5 min    | 01     |
| Denaturation         | 95 °C       | 30 sec   | 35     |
| Annealing            | 56 °C       | 30 sec   |        |
| Extension            | 72 °C       | 1.5 mn   |        |
| Final extension      | 72 °C       | 10 min   | 01     |
| Holding              | 4 °C        | Hold     | -      |

### 3.17.3 Electrophoresis

#### Process of Electrophoresis:

- Preparation of gel.
- Sample application in the gel.
- Adjustment of voltage or current (gel-electrophoresis about 70-100 volts).
- Set up run time about 30-60 minute
- When DNA migrated sufficiently, as judged from the migration of bromphenicol blue of loading buffer, the power supply was switched off.
- The gel stained in ethidium bromide (0.5  $\mu$ l/ml) for 10 minutes, in a dark place.
- The gel was distained in distilled water for 10 minutes. The distained gel was placed on the imaging system in the dark chamber of the image documentation system.
- The UV light of the system was switched on; the image was viewe on the monitor, focused, acquired and saved in an USB flash drive.

#### **3.17.4 Nucleotide sequence accession number and BLAST analysis**

The nucleotide sequence 16S rRNA gene region data was submitted to NCBI nucleotide sequence database. Using BLAST tool, phylogenetic tree, primer pairs were designed from NCBI database search tool.

## CHAPTER IV

### RESULTS

The present research was designed to determine the isolation, identification and antibiogram study of bacterial pathogens isolated from blood and nasopharyngeal swab samples of pneumonia patients from different hospitals of Dinajpur district of Bangladesh. The collected samples were subjected to various bacteriological examination such as cultural, biochemical techniques and antibiotic sensitivity pattern in the laboratory of the department of microbiology, HSTU, Dinajpur, for isolation and identification of bacteria. A total number of 40 samples were collected from pneumonia patients (3-15 years) for this study. Out of 40 samples, 15 were found to be positive for pneumonia and total 15 isolates were isolated. Result of morphological, staining, cultural, biochemical, antibiotic sensitivity pattern and percentage of incidence of isolated bacteria are presented in different tables.

#### 4.1. Results of microbial assessment of collected blood and nasopharyngeal swab samples by total viable counts

Serial dilution was performed to reduce the number of bacteria and also to obtain total viable counts. Samples (50µl) were spread on PCA plate up to dilution  $10^{-7}$ . For the growth of bacteria after 24 hours of incubation at 37°C aerobically and were indicated by the growth of circular, smooth, convex, and gray white or yellowish colonies. Then the number of colonies were observed and recorded. The numbers of total viable count are shown in table 3. In case of PCA, the highest total viable count  $8.6 \times 10^9$  cfu/ml was found in  $10^{-7}$  dilution and lowest  $1.6 \times 10^9$  cfu/ml in  $10^{-6}$  dilution.

**Table 3: Results of total viable counts in PCA agar**

| Dilution  | Number of colony | Result                   |
|-----------|------------------|--------------------------|
| $10^{-1}$ | More than 300    | TNTC                     |
| $10^{-2}$ | More than 300    | TNTC                     |
| $10^{-3}$ | More than 300    | TNTC                     |
| $10^{-4}$ | 280              | $5.6 \times 10^7$ cfu/ml |
| $10^{-5}$ | 115              | $2.3 \times 10^8$ cfu/ml |
| $10^{-6}$ | 80               | $1.6 \times 10^9$ cfu/ml |
| $10^{-7}$ | 43               | $8.6 \times 10^9$ cfu/ml |

**Legends:** PCA=Plate count agar, TNTC= Too numerous to count, CFU=Colony forming unit



**Plate No. 3:** Colony count on Plate Count Agar plate

## 4.2. Isolation and identification of bacteria by different bacteriological Methods:

### 4.2.1 Results of Cultural Examination

The cultural characteristics of *Streptococcus pneumoniae* on various media are presented in Table 4.

**Table 4. The results of cultural characteristics of the bacteria which were isolated from blood & nasopharyngeal swab samples of pneumonia patients**

| Name of Bacteria                | Samples             | Staining Characteristic  | Name of Media  | Colony Characteristics               |
|---------------------------------|---------------------|--|----------------|--------------------------------------|
| <i>Streptococcus pneumoniae</i> | Nasopharyngeal swab | Short chain forming Gram positive spherical cells, violet in colour. | Nutrient broth | Uniform turbidity                    |
|                                 |                     |  | Nutrient agar  | Convex, smooth & gray white colonies |
|                                 |                     |  | Blood agar     | Alpha hemolytic colony               |
|                                 | Blood               | Short chain forming Gram positive spherical cells, violet in colour. | Nutrient broth | Uniform turbidity                    |
|                                 |                     |  | Nutrient agar  | Smooth & gray white colonies         |
|                                 |                     |  | Blood agar     | Alpha hemolytic colony               |

#### 4.2.2 Results of nasopharyngeal swab sample inoculation on Nutrient broth, Nutrient agar & Blood agar

After inoculation of nasopharyngeal swab sample on Nutrient agar and Nutrient broth, it was observed that mat growth was found on Nutrient agar characterised by convex, circular, white colony & turbidity was found in Nutrient broth. Alpha hemolytic colonies were found on blood agar media.



**Plate No. 4:** Fresh Nutrient broth (Right), Turbidity on Nutrient broth (Left).

**Plate No. 5:** Fresh Nutrient agar plate (Right), Organisms on Nutrient agar showing convex, circular, white colony (Left).



**Plate No. 6:** Fresh blood agar plate (Right), Alpha hemolytic colonies on blood agar (Left).



### 4.2.3 Results of Blood sample inoculation on Nutrient broth, Nutrient agar & Blood agar

#### 4.2.3.1 Nutrient broth

Uniform turbidity was found on overnight culture of blood sample in Nutrient broth incubated at 37°C which indicates bacterial growth in the media.



**Plate No. 7:** Uniform turbidity

#### 4.2.3.2 Nutrient Agar

Nutrient agar plates are spread with the blood sample & revealed the growth of bacteria after 24 hours of incubation at 37°C aerobically which were indicated by the growth of smooth & gray white or yellowish colonies.



**Plate No. 8:** Culture on Nutrient Agar plate with smooth & gray white colonies

#### 4.2.3.3 Blood Agar


Blood sample of pneumonia patients are taken as inoculum & cultured on nutrient agar plates. Then colonies of the organism are taken from nutrient agar & spread on blood agar plates by sterile platinum wire loops (Subculture). After 24 hours of incubation at 37°C anaerobically (5% CO<sub>2</sub> in anaerobic jar), the growth of bacteria were indicated by characteristic alpha hemolytic colonies.



**Plate No. 9:** Alpha hemolytic colonies on blood agar

#### 4.2.4 Results of Microscopic Examination

Microscopic observation was performed to observe the morphology of the isolates. Gram positive isolates were found under microscope by oil immersion lens. Gram positive isolates were spherical chain shape cocci cells & showed purple coloured colonies under 100X microscopy.



**Plate No. 10:** Gram positive spherical chain shape cocci were found on Gram's staining.

### 4.3 Results of Biochemical Tests

Biochemical test was performed to confirm the bacteria that cause pneumonia in pneumonia patients. After observing the colony characters on different media and also gram staining, I have selected biochemical tests to identify bacteria. The following table shows the biochemical test results:


**Table 5: Results of Biochemical Tests**

| Name of the isolate             | Catalase | Oxidase | MR  | VP  | Indole | Lactose Fermentation | TSI | Bile Solubility |
|---------------------------------|----------|---------|-----|-----|--------|----------------------|-----|-----------------|
| <i>Streptococcus pneumoniae</i> | -ve      | -ve     | +ve | -ve | -ve    | +ve                  | +ve | +ve             |

**Legends:** +ve = positive, -ve = negative, MR= Methyl-Red, VP= Voges-Proskauer, TSI= triple sugar iron.

#### 4.3.1 Catalase Test


*Streptococcus pneumoniae* gives a negative result for Catalase test indicated by absence of bubble formation resulting from production of oxygen gas.



**Plate No. 11:** No bubble production indicates negative result in Catalase test.

### 4.3.2 Oxidase Test


*Streptococcus pneumoniae* gives a negative result in oxidase test indicated by no development of purple colour when the colonies of the organism came in contact with the filter paper soaked with oxidase reagent.



**Plate No. 12:** No purple colour development indicates a negative test & absence of oxydase enzyme.

### 4.3.3 Methyl-Red Test


*Streptococcus pneumoniae* gives a positive reaction for Methyl-Red test indicated by a bright red coloured ring formation in the reagent layer on the top of the medium.



**Plate No. 13:** Methyl-Red test result was positive indicated by colour change of the medium to bright red ring formation (right) & the left is control.

#### 4.3.4 Voges-Proskaur Test

*Streptococcus pneumoniae* shows a negative result for Voges-Proskaur test indicated by lack of rose red colour change of the medium.



No colour change indicates negative result

**Plate No. 14:** The result of Voges-Proskauer test was negative indicated by no red color change of the medium (right) & control (left).

#### 4.3.5 Indole Test

*Streptococcus pneumoniae* shows a negative result for indole test indicated by no appearance of a cherry red colored ring at the interface of the medium.




No cherry red color ring formation

**Plate No. 15:** No cherry red color ring formation indicates negative indole test (right) & control (left).

#### 4.3.6 Lactose Fermentation Test

*Streptococcus pneumoniae* shows a positive result for Lactose fermentation test indicated by colour change of the medium from red to orange or yellow.



Colour change of the medium

**Plate No. 16:** Colour change of the medium from red to orange or yellow indicates positive result (right) & control (left).

#### 4.3.7 TSI (Triple Sugar Iron) Test

*Streptococcus pneumoniae* shows a positive result for Triple Sugar Iron test indicated by yellowing of the medium (Acidic reaction). Acid slant or acid butt indicates that dextrose & sucrose were fermented or dextrose & lactose were fermented or all the three sugars, dextrose, lactose and sucrose were fermented.  $H_2S$  was not produced; because there was no blackening of the medium.




Yellowish colouration of the medium

**Plate No. 17:** Triple Sugar Iron test showing control (left) & positive (right).

#### 4.3.8 Bile Solubility Test

*Streptococcus pneumoniae* is bile soluble & gives a positive result in bile solubility test indicated by clearing of turbidity in test suspension.



**Plate No. 18:** Clearing of turbidity in test suspension indicates positive result (right) & the left is control.

#### 4.4 Frequency of pneumonia among pneumonia patients based on different categories

Out of 40 pneumonia patients, positive cases of pneumonia were found to be 37.5% & 15 isolates were isolated. Frequencies of pneumonia in pneumonia patients based on different categories were shown in table 6, 7, 8 & 9. Total 37.5% positive cases of pneumonia patients were shown in table 6.

**Table 6. Frequency of pneumonia among pneumonia patients**

| Total number of cases | No. of positive Cases | Percentage |
|-----------------------|-----------------------|------------|
| 40                    | 15                    | 37.5%      |

Highest frequency of pneumonia was seen in pneumonia patients of age 3-5 yrs and lowest frequency was noticed in age 13-15 yrs of age group which were shown in Table 7.

**Table 7. Frequency of pneumonia in pneumonia patients in relation to age**

| Age     | No. Examined | No. Positive | Percentage |
|---------|--------------|--------------|------------|
| 3-5yrs  | 12           | 6            | 50%        |
| 6-8yrs  | 10           | 4            | 33.33%     |
| 9-11yrs | 8            | 3            | 25%        |
| 12-15   | 10           | 2            | 20%        |
| Total   | 40           | 15           |            |

**Table 8. Distribution of pneumonia patients according to sample collection and types of bacteria**

| Name of Hospital                          | No. of Sample | No. of positive case (%) |
|---|---------------|--------------------------|
| M Abdur Rahim Medical<br>College Hospital | 20            | 8 (54.5)                 |
| Arobindo Shishu Hospital                  | 15            | 5 (36.36)                |
| Islami Bank Community<br>Hospital         | 5             | 2 (9.09)                 |
| Total                                     | 40            | 15                       |

Highest number of *Streptococcus pneumoniae* found in 3-5 years of age which were shown in table 9.

**Table 9: Distribution of organism based on age difference**

| Age       | Organisms                       |
|-----------|---------------------------------|
|           | <i>Streptococcus pneumoniae</i> |
| 3-5years  | 6 (7%)                          |
| 6-8years  | 4 (20%)                         |
| 9-11years | 3 (6.67%)                       |
| 12-15     | 2 (30%)                         |
| Total     | 15 (63.67%)                     |



#### 4.5 Prevalence of pneumonia among pneumonia patients

The table 10 represents the prevalence of pneumonia based on study area, age & socio-economic status. The present results reveals that the study area had no significant ( $P > 0.05$ ) effect but age ( $P < 0.05$ ) & socio-economic status ( $P < 0.05$ ) had significant effects on the prevalence of pneumonia in pneumonia patients. In study area, the highest prevalence was found in M Abdur Rahim Medical College Hospital (40%), followed by Arobindo Shishu Hospital (33.33%) & Islami Bank Community Hospital (40%) respectively. Among the age group, the prevalence of pneumonia was highest (50%) in 3-5 years age group, then 33.33% in 12-15 years age group, 25% in 6-8 years age group & 20% in 9-11 years age group. Highest prevalence of pneumonia was found in poor socio-economic status (54.54%), followed by medium (16.66%) & rich (16.66%) socio-economic condition respectively.

**Table 10: Prevalence of pneumonia based on study area, age & socio- economic status**


| Parameter             |  | No. examined | No. Positive | Prevalence (%) | P value |
|-----------------------|--|--------------|--------------|----------------|---------|
| Study area            | M Abdur Rahim Medical College Hospital | 20           | 8            | 40             | 0.061   |
|                       | Arobindu Shishu Hospital               | 15           | 5            | 33.33          |         |
|                       | Islami Bank Community Hospital         | 5            | 2            | 40             |         |
| Age                   | 3-5 years                              | 20           | 10           | 50             | 0.018   |
|                       | 6-8 years                              | 12           | 3            | 25             |         |
|                       | 9-11years                              | 5            | 1            | 20             |         |
|                       | 12-15 years                            | 3            | 1            | 33.33          |         |
| Socio-economic status | Poor                                   | 22           | 12           | 54.54          | 0.023   |
|                       | Medium                                 | 12           | 2            | 16.66          |         |
|                       | Rich                                   | 6            | 1            | 16.66          |         |

**Note:**  $P > 0.05$  means not significant,

$P < 0.05$  means statistically significant.

#### 4.6 Result of PCR Amplification, Sequencing of 16S rRNA Genes with Universal Primers and Phylogenetic Analysis of *Streptococcus pneumoniae*

16S rRNA gene region was amplified with the universal primers, Forward primer- 27F (5'AGAGTTTGATCCTGGCTCAG 3') Reverse primer- 1492R (5' TACCTTGTTACG ACTT 3'). PCR Amplification band was found at 1466 bp.



**Marker : 1kb + DNA Ladder**

**Plate No.19:** Result of amplification of 16S rRNA gene region of *Streptococcus pneumoniae* PCR. Note: PCR= Polymerase Chain Reaction, kb= kilo base.

#### 4.6.1 Contig Sequence of *Streptococcus pneumoniae*


Blast: 92%

Identified starin: *Streptococcus\_pneumoniae\_strain\_NBRC102642*.


>NR\_114172.1\_Streptococcus\_pneumoniae\_strain\_NBRC102642

GACGGCAGCACAGAGAAGCTTGCTTCTCGGGTGGCGAGTGGCGAACGGGTGA  
GTAACATATCGGAACGTACCGAGTAGTGGGGGATAACTGATCGAAAGATCAG  
CTAATACCGCATAACGTCTTGAGAGAGAAAGCAGGGGACCTTCGGGCCTTGCG  
CTATTCGAGCGGCCGATATCTGATTAGCTAGTTGGTGGGGTAAAGGCCTACCA  
AGGCGACGATCAGTAGCGGGTCTGAGAGGATGATCCGCCACACTGGGACTGA  
GACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATTTTGGACAATGG  
GCGCAAGCCTGATCCAGCCATGCCGCGTGTCTGAAGAAGGCCTTCGGGTTGT  
AAAGGACTTTTGTGTCAGGGAAGAAAAGGCTGTTGCTAATATCAGCGGCTGATG  
ACGGTACCTGAAGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAA  
TACGTAGGGTGGCAGCGTTAATCGGAATTACTGGGCGTAAAGCGGGCGCAGA  
CGGTTACTTAAGCAGGATGTGAAATCCCCGGGCTCAACCCGGGAACTGCGTT  
CTGAACTGGGTGACTCGAGTGTGTCAGAGGGAGGTAGAATTCCACGTGTAGC  
AGTGAAATGCGTAGAGATGTGGAGGAATACCGATGGCGAAGGCAGCCTCCTG  
GGACAACACTGACGTTTCATGCCCCGAAAGCGTGGGTAGCAAACAGGATTAGAT  
ACCCTGGTAGTCCACGCCCTAAACGATGTCAATTAGCTGTTGGGCAACCTGAT  
TGCTTGGTAGCGTAGCTAACGCGTGAAATTGACCGCCTGGGGAGTACGGTCG  
CAAGATTA AAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGATGAT  
GTGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATGTACGG  
AATCCTCCGGAGACGGAGGAGTGCCTTCGGGAGCCGTAACACAGGTGCTGCA  
TGGCTGTCGTCAGCTCGTGTGTCGTGAGATGTTGGGTAAAGTCCCGCAACGAGCG  
CAACCCTTGTCATTAGTTGCCATCATTAGTTGGGCACTCTAATGAGACTGCC  
GGTGACAAGCCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGGCCCTTAT  
GACCAGGGCTTCACACGTCATAACAATGGTTCGGTACAGAGGGTAGCCAAGCCG  
CGAGGCGGAGCCAATCTCACAAAACCGATCGTAGTCCGGATTGCACTCTGCA  
ACTCGAGTGCATGAAGTCGGAATCGCTAGTAATCGCAGGTCAGCATACTGCG  
GTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTGG  
GGGATACCAGAAGTAGGTAGGGTAACCGCAAGGAGCCCGCTTACCACGGTAT  
GCTTCT

### 4.6.2 Phylogenetic tree analysis of *Streptococcus pneumoniae*



### 4.6.3 Result of Electropherogram



#### 4.7 Results of Antibiotic Sensitivity Tests

Several commercially available antibiotics were used for *Streptococcus pneumoniae* are given in Table 11.


**Table 11: Result of antibiotic sensitivity test for *Streptococcus pneumoniae***

| Name of antibiotic with disc concentration | Zone of Inhibition (mm) | Interpretation |
|--|-------------------------|----------------|
| Penicillin (10)                            | -                       | R              |
| Amoxicillin (30)                           | -                       | R              |
| Ampicillin (25)                            | -                       | R              |
| Methicillin (5)                            | -                       | R              |
| Cloxacillin (1)                            | -                       | R              |
| Clindamycin (2)                            | -                       | R              |
| Ciprofloxacin (5)                          | -                       | R              |
| Vancomycin (30)                            | -                       | R              |
| Amikacin (30)                              | -                       | R              |
| Cefradin (25)                              | -                       | R              |
| Cefixime (5)                               | -                       | R              |
| Cefaclor (30)                              | -                       | R              |
| Cephalexin (30)                            | -                       | R              |
| Cefepime (30)                              | -                       | R              |
| Co-trimoxazole (25)                        | -                       | R              |
| Neomycin (30)                              | <b>19</b>               | <b>S</b>       |
| Kanamycin (30)                             | <b>21</b>               | <b>S</b>       |
| Streptomycin (10)                          | <b>29</b>               | <b>S</b>       |
| Erythromycin (15)                          | <b>20</b>               | <b>S</b>       |
| Azithromycin (30)                          | <b>24</b>               | <b>S</b>       |
| Bacitracin (10)                            | <b>18</b>               | <b>S</b>       |


**Legends: S= Sensitive, R= Resistant & I= Intermediate**

#### 4.7.1 Antibiotic Sensitivity pattern of *Streptococcus pneumoniae*


Antibiotic sensitivity test was carried out using disc diffusion technique on Mueller Hinton agar for all the bacterial isolates to the most common antibiotic agents. The antibiotic agents that were used in this study are given in the Table 13. The antibiotic study revealed that all of the isolates of *Streptococcus pneumoniae* were sensitive to Neomycin, Kanamycin & Streptomycin followed by Erythromycin, Azithromycin & Bacitracin. The isolates were resistant to Penicillin, Amoxicillin, Ampicillin, Methicillin, Cloxacillin, Clindamycin, Ciprofloxacin, Vancomycin, Amikacin & Co-trimoxazole followed by Cefradin, Cefixime, Cefaclor, Cephalexin & Cefepime.



**Plate No.20:** Antibiotic sensitivity test for *Streptococcus pneumoniae*




**Plate No. 21:** Antibiotic sensitivity test for *Streptococcus pneumoniae*




- Cloxacillin (R)
- Methicillin (R)
- Neomycin (S)
- Bacitracin (S)
- Kanamycin (S)

**Plate No. 22:** Antibiotic sensitivity test for *Streptococcus pneumoniae*




- Bacitracin (S)
- Streptomycin (S)
- Neomycin (S)
- Kanamycin (S)
- Azithromycin (S)

**Plate No. 23:** Antibiotic sensitivity test for *Streptococcus pneumoniae*




- Clindamycin (R)
- Cotrimoxazole (R)
- Erythromycin (S)
- Methicillin (R)
- Cloxacillin (R)

**Plate No. 24:** Antibiotic sensitivity test for *Streptococcus pneumoniae*



- Cefixime (R)
- Cefradin (R)
- Cefaclor (R)
- Cefepime (R)
- Cephalexin (R)

**Plate No. 25:** Antibiotic sensitivity test for *Streptococcus pneumoniae*



- Penicillin (R)
- Amikacin (R)
- Ciprofloxacin (R)
- Vancomycin (R)
- Amoxicillin (R)
- Ampicillin (R)

**Plate No. 26:** Antibiotic sensitivity test for *Streptococcus pneumoniae*



## CHAPTER V

### DISCUSSION

This study was conducted from January-November 2018 at different hospitals of Dinajpur district of Bangladesh. All microbiological analysis was carried out in microbiology laboratory of Hajee Mohammad Danesh Science and Technology University (HSTU), Dinajpur. The samples were collected from three main hospitals of Dinajpur district that includes: M Abdur Rahim Medical College Hospital, Dinajpur, Aurobindo Shishu Hospital, Dinajpur & Islami Bank Community Hospital, Dinajpur.

Out of 40 pneumonia patients, positive cases of pneumonia were found to be 37.5% & 15 isolates were isolated. The Frequency of pneumonia in relation to age were 3-5yrs (50%), 6-8yrs (33.33%), 9- 11yrs (25%) & 12-15 (20%). Distribution of organism based on age difference *Streptococcus pneumoniae* of 3-5 years (7%), 6-8 years (20%), 9-11 years (6.67%) & 12-15 years (30%). The present study reveals that the study area had no significant ( $P > 0.05$ ) effect but age ( $P < 0.05$ ) & socio-economic status ( $P < 0.05$ ) had significant effects on the prevalence of pneumonia in pneumonia patients. In study area, the highest prevalence was found in M Abdur Rahim Medical College Hospital (40%), followed by Arobindo Shishu Hospital (33.33%) & Islami Bank Community Hospital (40%) respectively. Among the age group, the prevalence of pneumonia was highest (50%) in 3-5 years age group, then 33.33% in 12-15 years age group, 25% in 6-8 years age group & 20% in 9-11 years age group. Highest prevalence of pneumonia was found in poor socio-economic status (54.54%), followed by medium (16.66%) & rich (16.66%) socio-economic condition respectively.

Antibiotic sensitivity test was carried out using disc diffusion technique on Mueller Hinton agar for all the bacterial isolates to the most common antibiotic agents. The antibiotic study revealed that all of the isolates of *Streptococcus pneumoniae* were sensitive to Neomycin, Kanamycin & Streptomycin followed by Erythromycin, Azithromycin & Bacitracin. The isolates were found resistant to Penicillin, Amoxicillin, Ampicillin, Methicillin, Cloxacillin, Clindamycin, Ciprofloxacin, Vancomycin, Amikacin & Co-trimoxazole followed by Cefradin, Cefixime, Cefaclor, Cephalexin & Cefepime.

In Rio de Janeiro, Barroso *et al.*, (2012) isolated, from patients with pneumonia, penicillin-resistant *S. pneumoniae* (clone Spain9V-ST156) linked to serotype. Several

authors reported rates of penicillin resistance of *S. pneumoniae*, isolated from patients with pneumonia & meningitis, ranging from 21.4% to 27.1%, compatible with the 25.5% rate found here. On the other hand, lower values were observed in the state of Parana (15%) and in Salvador (13%-19%), and higher than 50% in Cuba, El Salvador, Honduras and Mexico. For the other non-meningeal pneumococcal infections, our research detected 3% of strains with intermediate resistance and 0.1% with full resistance to penicillin. According to Negrini (2010), in the municipality of Ribeirao Preto, children younger than 5 years presented 3.5% of *S. pneumoniae* with intermediate resistance, and none presented full resistance to penicillin. In 2012, in Brazil, full resistance was not observed to penicillin either, and intermediate resistance was 7.5% and 3.9% for children younger and older than 5 years, respectively.

In Argentina, for children younger than 5 years, 100% of the strains were susceptible to penicillin. In this study, among the pneumococci isolated from patients with pneumonia, just 0.1% was totally resistant to penicillin and 3% of the isolates from non-meningeal infections presented intermediate resistance to penicillin. This piece of data reinforces the consensus of some researches that concluded that patients with pneumonia treated with penicillin presented similar clinical evolution.

In Guatemala and Mexico, a superior proportion of *S. pneumoniae* resistant to ceftriaxone (16.7% and 16.5%, respectively) for non-meningeal infections was verified. In Brazil, in nonmeningeal infections, a rate of 3% of intermediate resistance to ceftriaxone was reported, with no isolation of the pneumococcus with full resistance, a value similar to the one of the region researched in this work. In general, the resistance profile of *S. pneumoniae* to ceftriaxone is low, yet, the importance of monitoring resistance levels is stressed due to the excellence of this antimicrobial for treatment of bacterial meningitis. Strains of *S. pneumoniae* resistant to penicillin are frequently associated with resistance to other classes of antimicrobials. In Porto Alegre, among the 18 penicillin-resistant pneumococcus strains, seven were resistant to at least two other drugs. In this research, 0.9% of multi-resistant *S. pneumoniae* was reported, with simultaneous resistance to penicillin & erythromycin. In the USA, it commonly relates to serotype 19A after the introduction of pneumococcal conjugate vaccine. Besides, *S. pneumoniae* with full and simultaneous resistance to penicillin and ceftriaxone were observed in eight (1%) of the patients.

## CHAPTER VI

### CONCLUSION

*Streptococcus pneumoniae* is a leading cause of bacterial pneumonia in children worldwide. In the present study, it was observed that pneumonia was most commonly found in 3-5 years age group & in poor socio-economic condition. The antibiotic study revealed that all of the isolates of *Streptococcus pneumoniae* were resistant to most of the drugs, but found sensitive to Neomycin, Kanamycin & Streptomycin followed by Erythromycin, Azithromycin & Bacitracin. The increasing incidence of antibiotic-resistant *S. pneumoniae* strains are becoming a great problem to treat & control this bacterial species. Use of antibiotics without the recommendation of registered physicians is one of the most important causes of this problem.

## REFERENCES

- Aleksandra K, Wierzbowski, James A, Karlowsky, Heather J, Adam, 2013. Evolution and molecular characterization of macrolide-resistant *Streptococcus pneumoniae* in Canada between 1998 and 2008. doi: 10.1093/ jac/dkt332 Advance Access publication.
- Anis Raddaoui, Alexandra S, Simoes, Rekaya Baaboura, Sofia Felix, Wafa Achour, Tarek Ben Othman, Mohamed Bejaoui, Raquel Sa-Leao , Assia Ben Hassen, 2015. Serotype Distribution, Antibiotic Resistance and Clonality of *Streptococcus pneumoniae* Isolated from Immunocompromised Patients in Tunisia. <https://doi.org/10.1371/journal.pone.0140390>
- Araceli Soto-Noguero, Maria Noemi Carnalla-Baraja, Fortino Soloo rzano-Santo, Josee Luis Arrendondo-Garcia, 2016. *Streptococcus pneumoniae* as cause of infection in infants less than 60 days of age: serotypes and antimicrobial susceptibility. *International Journal of Infectious Diseases*, 42: 69–73.
- Ataiza C, Vieira, Marizoneide C, Gomes, Mauricio Rolo Filho, 2007. *Streptococcus pneumoniae*: a study of strains isolated from cerebrospinal fluid. *Jornal de Pediatria* - 83:1. doi 10.2223/JPED.1580.
- Aura Lucia Leal and Elizabeth Castaneda, 1997. Antibiotic susceptibility of *Streptococcus pneumoniae* colonizing the nasopharynx of Colombian children with pneumonia. *Rev Panam Salud Publica/Pan Am J Public Health* 2(4).
- Barroso DE, Godoy D, Castineiras TM, 2012.  $\beta$ -lactam resistance, serotype distribution, and genotypes of meningitis-causing *Streptococcus pneumoniae*, Rio de Janeiro, Brazil. *Pediatr Infect Dis J*, 31: 30-6.
- Berezin EN, Carvalho ES, Casagrande S, Brandileone MC, Mimica IM, Farhat CK, 1996. *Streptococcus pneumoniae* penicillin-nonsusceptible strains in invasive infections in Sao Paulo, Brazil. *Pediatr Infect Dis J*, 15:1051-3.
- Berman S, 1991. Epidemiology of acute respiratory infections in children of developing countries. *Rev Infect Dis*; 13: 454–462.

- Bryce J, Boshi-Pinto C, Shibuya K, Black RE, 2005. WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. *Lancet*, 365:1147-52.
- Castaneda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, Brandao AP, 2009. Laboratory-based surveillance of *Streptococcus pneumoniae* invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. *Pediatr Infect Dis J*, 28:265-70.
- Chinwendu Onwubiko, Edwin Swiatlo and Larry S. McDaniel, 2008. Cross-Sectional Study of Nasopharyngeal Carriage of *Streptococcus pneumoniae* in Human Immunodeficiency Virus-Infected Adults in the Conjugate Vaccine Era. *Journal of Clinical Microbiology*. 46 (11): 3621–3625.
- Christina S, Thornton, Erin Brown L, Joenel Alcantara, Harvey R Rabin, and Michael Parkins D, 2015. Prevalence and impact of *Streptococcus pneumoniae* in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study. *Journal List BMC Pulm Med* v.15;. PMC4434824.
- Collignon PJ, Bell JM, 1996. Drug-resistant *Streptococcus pneumoniae*: The beginning of the end for many antibiotics? Australian Group on Antimicrobial Resistance (AGAR) *Med J Aust.*; 164:64–7.
- Cristina RM, Yoshioka, Marina B, Martinez, Maria CC, Brandileone, 2011. Analysis of invasive pneumonia-causing strains of *Streptococcus pneumoniae*: serotypes and antimicrobial susceptibility. *Jornal de Pediatria*-87(1):71. doi:10.2223/JPED.2063.
- Devine, VT, Cleary, DW, Jefferies, JM, Anderson, R, Morris, DE, Tuck, AC, Gladstone, RA, O'doherty, G, Kuruparan, P, Bentley, SD, Faust, SN & Clarke, SC, 2017. The rise and fall of pneumococcal serotypes carried in the PCV era. *Vaccine*, 35, 1293-1298.
- Ebruke, CN, 2018. Molecular epidemiological and pathogenesis studies of *Streptococcus pneumoniae* serotype 1 strains from West Africa. MPhil thesis, London School of Hygiene & Tropical Medicine. DOI: <https://doi.org/10.17037/PUBS.04647232>

- Elina Lahti, 2008. Childhood Community-acquired Pneumonia. ISSN 0355-9483
- Elizeus Rutebemberwa, Betty Mpeka, George Pariyo, Stefan Peterson, Edison Mworozzi, Freddie Bwanga & Karin KaLlander, 2015. High prevalence of antibiotic resistance in nasopharyngeal bacterial isolates from healthy children in rural Uganda: A cross-sectional study. <https://doi.org/10.3109/03009734.2015.1072606>
- Eric S Donkor, Ebenezer Foster-Nyarko, and Christabel C Enweronu-Laryea, 2013. Relationship between antibiotic resistance and sickle cell anemia: preliminary evidence from a pediatric carriage study in Ghana. doi: 10.2147/IDR.S40062. PMID: 23930075. PMID: PMC3733876.
- Fen Pan, Lizhong Han, Weichun Huang, Jin Tang, Shuzhen Xiao, Chun Wang, Huihong Qin, Hong Zhang, 2015. Serotype Distribution, Antimicrobial Susceptibility, and Molecular Epidemiology of *Streptococcus pneumoniae* Isolated from Children in Shanghai, China. <https://doi.org/10.1371/journal.pone.0142892>.
- Fouzia Zeeshan Khan, Samina Baig, Samreen Zameer and Shaheen Sharafat, 2017. Prevalence and antibiotic resistance pattern of *Streptococcus pneumoniae*, isolated from invasive and non-invasive infections in a tertiary care hospital of karachi. Issn: 2320-5407. Int. J. Adv. Res. 5(4): 825-831.
- Friedland IR, Klugman KP, 1992. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child.;146:920-3.
- Geng Q, Zhang T, Ding Y, Tao Y, Lin Y, 2014. Molecular Characterization and Antimicrobial Susceptibility of *Streptococcus pneumoniae* Isolated from Children Hospitalized with Respiratory Infections in Suzhou, China. PLoS ONE 9(4): e93752. doi:10.1371/journal.pone.0093752.
- Gray BM, Converse GM III, Dillon HC Jr, 1980. Epidemiologic studies of *Streptococcus pneumoniae* in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis; 142: 923-933.
- Hicks LA, Monnet DL, Roberts RM, 2010. Increase in pneumococcus macrolide resistance, USA. Emerg Infect Dis 16: 896-7.

<https://microbiologyinfo.com/biochemical-test-and-identification-of-streptococcus-pneumoniae/>

<https://paramedicsworld.com/streptococcus-pneumoniae-pneumococcus/biochemical-tests-for-streptococcus-pneumoniae/medical-paramedical-studynotes#.XDON99IzbiU>

Indre Staceviciene, Sigita Petraitiene, Daiva Vaiciuniene, Tomas Alasevicius, Jurate Kirsliene and Vytautas Usonis. 2016. Antibiotic resistance of *Streptococcus pneumoniae*, isolated from nasopharynx of preschool children with acute respiratory tract infection in Lithuania. DOI 10.1186/s12879-016-1544-9.

Ishida T, Maniwa K, Kagioka H, Hirabayashi M, Onaru K, Tomioka H, 2008. Antimicrobial susceptibilities of *Streptococcus pneumoniae* isolated from adult patients with community-acquired pneumonia in Japan. *Respirology*, 13:240–6.

Jailton Azevedo, Eder Silva dos Anjos, Soraia Cordeiro M, 2016. Genetic profiles and antimicrobial resistance of *Streptococcus pneumoniae* non-PCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil. *Journal of Medical Microbiology*, 65, 1164–1170. DOI 10.1099/jmm.0.000346.

Jill A, Hoffman MD, Edward O, Mason PhD, Gordon E, Schutze MD, Tina Q, 2003. *Streptococcus pneumoniae* Infections in the Neonate. *PEDIATRICS*, 112 (5).

Joaquim C, Rodrigues, Luiz VF, Silva Filho & Andrew Bush, 2002. Etiological diagnosis of pneumonia –a critical view. *Jornal de Pediatria*, 78 (2).

Jorg J. Ruhe Rodrigo Hasbun, 2003. *Streptococcus pneumoniae* Bacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance. 36(9):1132–1138. <https://doi.org/10.1086/374556>.

Katherine L, O'Brien Lara J, Wolfson, James Watt P, Emily Henkle, Maria Deloria-Knoll, 2009. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates, 374 (12).

Kiran Chawla, Bimala Gurung, Chiranjay Mukhopadhyay and Indira Bairy, 2010. Reporting Emerging Resistance of *Streptococcus pneumoniae* from India. doi: 10.4103/0974-777X.59245.

- Kumar D, Humar A, Plevneshi A, Siegal D, Franke N, Green K, 2008. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. *Bone Marrow Transplant*, 41(8):743–7. Epub 2008/01/08. doi: 1705964 [pii] pmid:18176614.
- Lalitha MK, Pai R, Manoharan A, 2002. Multidrug-resistant *Streptococcus pneumoniae* from India. *The Lancet*; 3:445.
- Lian Xue, Kaihu Yao, Guilin Xie, Yuejie Zheng, Chuanqing Wang, 2010. Serotype Distribution and Antimicrobial Resistance of *Streptococcus pneumoniae* Isolates That Cause Invasive Disease among Chinese Children. DOI: 10.1086/650534.
- Marta Ines C, Medeiros<sup>1</sup>, Samanta Cristine G, Almeida<sup>1</sup>, Sergio Bokermann, 2017. Suscetibilidade antimicrobiana de *Streptococcus pneumoniae* isolados de pacientes na macrorregiao nordeste do estado de Sao Paulo, Brasil, entre 1998 e 2013. First submission on 14/09/16; last submission on 14/09/16; accepted for publication on 19/04/17; published on 20/06/17.
- Matthew H, Samore MD, Michael K, Magill MD, Stephen C, Alder, MS, Elena Severina, 2001. High Rates of Multiple Antibiotic Resistance in *Streptococcus pneumoniae* From Healthy Children Living in Isolated Rural Communities: Association With Cephalosporin Use and Intrafamilial Transmission, 108 (4).
- Melo-Cristiano JL, Santos M, Ramirez M, 2006. The Viriato study: update of antimicrobial susceptibility data of bacterial pathogens from community acquired respiratory tract infections in Portugal in 2003 and 2004. *Rev Port Pneumol*, 12: 9-30.
- Merja Rantala, 2009. Antimicrobial resistance in *Streptococcus pneumoniae* in Finland with special reference to macrolides and telithromycin. ISBN 978-952-245-058-6 (pdf).
- Michel Kengne, Marlise Beatrice Bidzogo Lebogo, Julius Mbekem Nwobegahay, Bienvenue Etogo Ondigui, 2018. Antibiotics susceptibility pattern of *Streptococcus pneumoniae* isolated from sputum cultures of human immunodeficiency virus infected patients in Yaoundé, Cameroon. ISSN 1937-8688.



- Monica Luminos, Olga Dorobat, George Jugulete, Gabriel Adrian Popescu, Dragos Florea, Anca Draganescu, Anca Streinu Cercel, Alexandru Rafila, 2014. Nasopharyngeal carriage of *Streptococcus pneumoniae* in Romanian children before the introduction of the pneumococcal conjugated vaccination into the national immunization programme: a national, multi-centre, cross-sectional observational study, 29:169–173. DOI: <https://doi.org/10.1016/j.ijid.08.020>.
- Mulholland K, 1999. Strategies for the control of pneumococcal diseases. *Vaccine*; 17:79–84.
- Musher D, 1992. Infections caused by *Streptococcus pneumoniae*: clinical spectrum, pathogenesis, immunity, and treatment. *Clin Infect Dis*; 14:801–809.
- Nao Suzuki, Mayumi Yuyama, Sinsaku Maeda, Haruhiko Ogawa, Kazuyuki Mashiko and Yusuke Kiyoura, 2006. Genotypic identification of presumptive *Streptococcus pneumoniae* by PCR using four genes highly specific for *S. pneumoniae*. *Journal of Medical Microbiology*, 55:709–714. DOI 10.1099/jmm.0.46296-0.
- Nasrin D, Collignon PJ, Wilson EJ, Pilotto LS and Douglas RM, 1999. Antibiotic resistance in *Streptococcus pneumoniae* isolated from children. *J. Paediatr. Child Health*, 35:558–561.
- Negrini BVM, 2010. Doenças invasivas causadas pelo *Streptococcus pneumoniae* em crianças: sorotipos, resistencia a penicilina in vitro influencia dessa resistencia sobre o prognostico de crianças tratadas com penicilina. [Thesis]. Ribeirao Preto, São Paulo: Faculdade de Medicina de Ribeirão Preto/USP.
- O' Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, HIB & Pneumococcal Global Burden of Disease study T, 2009. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet*, 374, 893-902.
- O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, 2009. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet*, 374 (9693):893–902. Epub 2009/09/15. doi: S0140-6736(09)61204-6 [pii] pmid:19748398.

- Paisley JW, Lauer BA, Mcintosh K, Glode MP, Schachter J, Rumack C, 1984. Pathogens associated with acute lower respiratory tract infection in young infants. *Pediatr Infect Dis J*; 3:14–19.
- Palleres R, Gudiol F, Linares J, Ariza J, Rufi G, Murqui L, 1987. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. *N Engl J Med.*; 317:18-22.
- Rapee Thummeepak, Nontapat Leerach, Duangkamol Kunthalert, Udomsak Tangchaisuriya, Aunchalee Thanwisai, Sutthirat Sitthisak, 2015. High Prevalance of multi-drug resistant *Streptococcus pneumoniae* among healthy children in Thailand. DOI: <https://doi.org/10.1016/j.jiph.2014.11.002>. 8(3):274–281.
- Reinert RR, 2009. The antimicrobial resistance profile of *Streptococcus pneumoniae*. *Clin Microbiol Infect.* 15:7-11.
- Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H, 2004. WHO Child Health Epidemiology Reference Group. Global estimate of the incidence of clinical pneumonia among children under five years of age. *Bull World Health Organ.* 82:895-903.
- Sabrina Moyo J, Martin Steinbakk, Said Aboud, Namala Mkopi, 2012. Penicillin resistance and serotype distribution of *Streptococcus pneumoniae* in nasopharyngeal carrier children under 5 years of age in Dar es Salaam, Tanzania. *Journal of Medical Microbiology*, 61:952–959 DOI 10.1099/jmm.0.042598-0.
- Sedigheh Rafiei Tabatabaei , Mohammad Rahbar , Ali Nazari Alam, Fatemeh Fallah , Ali Hashemi , Masoud Yousefi , Hamidreza Hourri and Abdollah Karimi, 2017. Detection of *pbp2b* Gene and Antimicrobial Susceptibility Pattern of *Streptococcus pneumoniae* Isolates in Tehran Hospitals, Iran. DOI: 10.5812/pedinfect.38891.
- Semczuk K, Pawinska A, Borowiec D, Garczewska B, Kaminska W, Dzierzanowska-Fangrat K, 2010. Antimicrobial resistance of *Streptococcus pneumoniae* isolated from children with nasopharyngeal carriage and infections during the 9-year period. *Pediatric Research*, 68:438.

- Shann F, 1986. Etiology of severe pneumonia in children in developing countries. *Pediatr Infect Dis J*; 5:247–252.
- Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, 2004. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. *Clin Infect Dis.*; 38:1570-8.
- Songyin Huang, Xiaoqiang Liu, Weisi Lao, Suhua Zeng, Huiqi Liang, Rihui Zhong, Xinlu Dai<sup>1</sup>, Xiquan Wu, Hongyu Li and Yandan Yao, 2015. Serotype distribution and antibiotic resistance of *Streptococcus pneumoniae* isolates collected at a Chinese hospital from 2011 to 2013. DOI 10.1186/s12879-015-1042-5.
- Susan Githii, Gunturu Revathi, Anne Muigai, Samuel Kariuki, 2013. Carriage rate and serotypes of *Streptococcus pneumoniae* amongst children in Thika Hospital, Kenya, 2, (1). <http://dx.doi.org/10.4102/ajlm.v2i1.45>.
- Susan S. Chiu, Pak Leung HO, Frankie KH. Chow, Kwok Yung Yuen and Lung Lau YU, 2001. Nasopharyngeal Carriage of Antimicrobial-Resistant *Streptococcus pneumoniae* among Young Children Attending 79 Kindergartens and Day Care Centers in Hong Kong. *Antimicrobial agents and Chemotherapy*, 0066-4804/01/\$04.000. DOI: 10.1128/AAC.45.10.2765–2770.2001 Oct. 2001, p. 2765–2770, 45:10.
- Takafumi Okada, Yoshitake Sato, Yoshikiyo Toyonaga, Hideaki Hanaki and Keisuke Sunakawa<sup>1</sup>, 2016. Nationwide survey of *Streptococcus pneumoniae* drug resistance in the pediatric field in Japan. *Pediatrics International*, 58:192–201 doi: 10.1111/ped.12781.
- Thi Thi Htoon, Nan Aye Thida Oo, Wah Wah Aung, Hlaing Myat Thu, Mon Mon, Masaya Yamaguchi, Shigetada Kawabata, Kyaw Zin Thant, 2018. "Serotype Distribution and Antimicrobial Susceptibility Profile of *Streptococcus pneumoniae* Among Myanmar Children with Acute Respiratory Infection".

- Ubukata K, Chiba N, Hanada S, Morozumi M, Wajima T, Shouji M, Iwata S. & Invasive Pneumococcal Diseases Surveillance Study G, 2015. Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013. *Emerg Infect Dis*, 21:1956-65.
- Vilhjalmur Arason A, Karl Kristinsson G, Johann Sigurdsson A, Gudrun Stefansdottir, Sigvard Molstad and Sigurdur Gudmundsson, 1996. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. *BMJ*; 313 doi: <https://doi.org/10.1136/bmj.313.7054.387> (Published 17 August 1996) Cite this as: *BMJ* 1996; 313:387.
- Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, 2000. Increasing prevalence of multidrug-resistant *Streptococcus pneumoniae* in the United States. *N Engl J Med.*; 343:1917-24.
- Xiang Ma, Ruizhen Zhao, Zhuoya Ma, Kaihu Yao, Sangjie Yu, Yuejie Zheng ,Yonghong Yang , 2013. Serotype Distribution and Antimicrobial Resistance of *Streptococcus pneumoniae* Isolates Causing Invasive Diseases from Shenzhen Children's Hospital. <https://doi.org/10.1371/journal.pone.0067507>.
- Yu VL, Chiou CC, Feldman C, Ortvist A, Rello J, Morris AJ, 2003. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered and clinical outcome. *Clin Infect Dis*; 37:230-7.